JP2012001537A - Medicine composed of biphenyl acetamide derivative - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a medicine composed of a compound useful for a treating agent or preventing agent against various epileptic seizures such as partial seizures and/or generalized seizures.SOLUTION: The medicine includes the compound represented by formula (I). In the formula: R, Rand Rare each a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a 1-6C alkyl group, a 1-6C alkoxy group substituted with a fluorine atom, or the like; Rand Rare each a hydrogen atom, a fluorine atom, a chlorine atom, a 1-6C alkyl group, a 1-6C alkoxy group substituted with a fluorine atom, or the like; Rand Rare each a hydrogen atom, a fluorine atom, a methyl group, an ethyl group, a hydroxyl group, or the like; and Rand Rare each a hydrogen atom, a 1-6C alkyl group, or the like.

Description

  The present invention relates to a pharmaceutical comprising a novel biphenylacetamide derivative useful as a therapeutic agent for epilepsy.

  Epilepsy is a chronic disease in which paroxysmal movement, consciousness, sensory abnormalities, and behavioral abnormalities resulting from excessive excitation of brain neurons are repeated. And one in three cases of this disease is refractory epilepsy that shows resistance to existing drug treatments. Epilepsy seizures can be broadly classified into partial seizures and generalized seizures. Partial seizures indicate behavioral abnormalities and electroencephalographic abnormalities that start in a limited area of the unilateral cerebral hemisphere. Partial seizures are further classified into simple partial seizures, complex partial seizures, and secondary generalized tonic-clonic seizures. On the other hand, generalized seizures are seizures that do not show a localized seizure origin and manifest symptoms in bilateral hemispheric synchronization. The usual clinical symptoms of generalized seizures are characteristic systemic motor symptoms with loss of consciousness. In addition, the electroencephalogram at the time of seizure is bilaterally synchronized. Absence seizure, atypical absence seizure, myoclonic seizure, tonic seizure, clonic seizure, tonic-clonic seizure ), Atonic seizure, West syndrome and Lennox-Gastaut syndrome are classified as generalized seizures.

  The treatment of these various epileptic seizures is centered on pharmacological treatment, and despite the fact that various antiepileptic drugs have been prescribed for a long time, they are still widespread for partial seizures and general seizures (especially absence seizures and myoclonic seizures). The only effective antiepileptic drug is valproic acid. However, valproic acid is not a sufficiently satisfactory drug in terms of effects and side effects, and there are still intractable patients whose effects cannot be expected with existing therapeutic agents. Therefore, there is a demand for the development of a therapeutic agent that exhibits a wide range of efficacy and therapeutic resistance for partial seizures and / or general seizures, and is excellent in safety.

  Many antiepileptic drugs have no specific mechanism of action, and various mechanisms are considered to act in a complex manner. Therefore, some of the drugs that have been developed as antiepileptic drugs so far have been widely used in multiple neurological and mental disorders (Pawel, DZ et al., Non-epilepsy use of antiepileptic drugs, Pharmacological Reports, 2006, 58, 1-12). For example, bipolar disorder (manic-depressive disorder) that repeats epilepsy and depression and causes mood modulation has few specific treatments (lithium only), but some antiepileptic drugs have a mood-stable effect (mood stabilizer) is recognized and used. Carbamazepine is used first (Brambilla, P., Barrale, F., Soares, JC, Perspectives on the use of anticonvulsants in the treatment of bipolar disorder, International Journal of Neuropsychopharmacology, 2001, 4, 421-446), followed by Valproic acid has been used. In particular, valproic acid has been used in clinical practice as a first-line drug for bipolar epilepsy (Angel, I and Horovitz, T., Bipolar disorder and valproic acid). However, there are not enough drugs for the treatment of one bipolar depressive state, and a new drug that exhibits high usefulness for both epilepsy and depression is awaited.

  Patent Document 1 describes biphenylalkylamines represented by the following general formula having an antiarrhythmic action.

Wherein X is hydrogen or halogen; R ¹ is hydrogen, hydroxyl, CN, CONH ₂ or COOR ⁵ , where R ⁵ is hydrogen or lower alkyl;
R ² is hydrogen or C _1-3 alkyl; Z is — (CH ₂ ) _n — or

Wherein n is 2, 3 or 4; R ³ and R ⁴ are each selected from pyrrolidino, piperidino and morpholino together with hydrogen, lower alkyl, lower alkenyl, phenylalkyl, or a nitrogen atom It is a group forming a cyclic structure. )
In this compound, biphenyl and an amino group are bonded via 3 or more carbon atoms, and the chemical structure is different from the compound represented by the following formula (I).

  Patent Document 2 describes a benzene derivative represented by the following general formula useful as an Hsp90 family protein inhibitor.

[Wherein n represents an integer of 0 to 10,
R ¹ is a hydrogen atom, hydroxy, cyano, carboxy, nitro, halogen, substituted or unsubstituted lower alkyl, —CONR ⁷ R ⁸ (wherein R ⁷ and R ⁸ are the same or different, and a hydrogen atom, substituted or non-substituted R ² represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, etc .; R ³ and R ⁵ is the same or different and represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like; R ⁴ and R ⁶ are the same or different and represent a hydrogen atom, hydroxy, halogen, cyano, substituted or unsubstituted aryl, or the like. To express. ]
Since the compound has a hydroxyl group or an alkoxy group as an essential substituent on the benzene ring, the compound has a different chemical structure from the compound represented by the following formula (I).

US Pat. No. 4,277,471 European Patent 1,704,856

  An object of the present invention is to provide a medicament comprising a novel compound useful as an antiepileptic drug.

  As a result of intensive studies, the present inventors have found that a novel compound represented by the following formula (A) exhibits a strong anticonvulsant action and completed the present invention. According to the present invention, there is provided a medicament comprising a biphenylacetamide derivative represented by the following formula (A) (hereinafter sometimes referred to as “compound according to the present invention”).

  [Claim 1] The following formula (A):

[Where:
R ¹ , R ² , R ³ , R ^a and R ^b are bonded one by one to any substitutable carbon atom on the benzene ring to which they are bonded, and are the same or different and each represents a hydrogen atom, a fluorine atom, chlorine Represents an atom, bromine atom, C _1-6 alkyl, C _1-6 alkoxy substituted with 1 to 3 fluorine atoms, C _1-6 alkyl-S (O) _n — or cyano, S (O) _n -may be substituted with 1 to 5 fluorine atoms, wherein any ^{two of} R ¹ , R ² , R ³ , R ^a and R ^b are 2 When '-methyl and 3'-methyl, any one of the remaining groups is a group other than a hydrogen atom;
R ⁴ , R ⁵ , R ^c and R ^d are bonded one by one to any substitutable carbon atom on the benzene ring to which they are bonded, and are the same or different and each represents a hydrogen atom, a fluorine atom, a chlorine atom, C _1-6 alkyl, C _1-6 alkoxy substituted with 1 to 3 fluorine atoms, C _1-6 alkyl-S (O) _n —, cyano or nitro, wherein the alkyl or alkyl-S (O) _n − may be substituted with 1 to 5 fluorine atoms,
R ⁶ and R ⁷ are the same or different and each represents a hydrogen atom, a fluorine atom, methyl, ethyl, a hydroxyl group or C _1-6 alkoxy (however, when one is a hydroxyl group, the other is a fluorine atom, a hydroxyl group or C _{1) -6} not alkoxy), or together with the carbon atoms to constitute the C _3-6 cycloalkyl which binds to, the methyl, ethyl, alkoxy and cycloalkyl are optionally substituted with 1-5 fluorine atoms You may,
R ⁸ and R ⁹ are the same or different and each represents a hydrogen atom, C _1-6 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl or C _3-6 cycloalkyl, and the alkyl, cycloalkyl-alkyl And cycloalkyl may be substituted with 1 to 5 fluorine atoms,
n represents an integer of 0 to 2,
However, when R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ^a , R ^b , R ^c and R ^d are all hydrogen atoms and R ⁶ and R ⁷ are both hydrogen atoms, R ^{One of 8} and R ⁹ is a hydrogen atom,
When R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ^a , R ^b , R ^c and R ^d are all hydrogen atoms and any one of R ⁶ and R ⁷ is alkoxy, R ⁸ and R ⁹ are the same or different and each represents a hydrogen atom, C _1-3 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl or C _3-6 cycloalkyl. ]
Or a hydrate or solvate thereof.
[Item 2] The following formula (I):

[Where:
R ¹ , R ² and R ³ are bonded one by one to any substitutable carbon atom on the benzene ring to which they are bonded, and are the same or different and are each hydrogen atom, fluorine atom, chlorine atom, bromine _Represents an atom, C _1-6 alkyl, C _1-6 alkoxy substituted with 1 to 3 fluorine atoms, C _1-6 alkyl-S (O) _n — or cyano, the alkyl or alkyl-S (O ) _N -may be substituted with 1 to 5 fluorine atoms, wherein any ^{two of} R ¹ , R ² and R ³ are 2′-methyl and 3′-methyl. When the remaining group is a group other than a hydrogen atom,
R ⁴ and R ⁵ are bonded one by one to any substitutable carbon atom on the benzene ring to which they are bonded, and are the same or different and each represents a hydrogen atom, a fluorine atom, a chlorine atom, C _1-6 Alkyl, C _1-6 alkoxy substituted with 1 to 3 fluorine atoms, C _1-6 alkyl-S (O) _n —, cyano or nitro, wherein the alkyl or alkyl-S (O) _n — is , May be substituted with 1 to 5 fluorine atoms,
R ⁶ and R ⁷ are the same or different and each represents a hydrogen atom, a fluorine atom, methyl, ethyl, a hydroxyl group or C _1-6 alkoxy (however, when one is a hydroxyl group, the other is a fluorine atom, a hydroxyl group or C _{1) -6} not alkoxy), or together with the carbon atoms to constitute the C _3-6 cycloalkyl which binds to, the methyl, ethyl, alkoxy and cycloalkyl are optionally substituted with 1-5 fluorine atoms You may,
R ⁸ and R ⁹ are the same or different and each represents a hydrogen atom, C _1-6 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl or C _3-6 cycloalkyl, and the alkyl, cycloalkyl-alkyl And cycloalkyl may be substituted with 1 to 5 fluorine atoms,
n represents an integer of 0 to 2,
However, when R ¹ , R ² , R ³ , R ⁴ and R ⁵ are all hydrogen atoms and R ⁶ and R ⁷ are both hydrogen atoms, either R ⁸ or R ⁹ is a hydrogen atom. Yes,
When R ¹ , R ² , R ³ , R ⁴ and R ⁵ are all hydrogen atoms and either one of R ⁶ and R ⁷ is alkoxy, R ⁸ and R ⁹ are the same or different and Atom, C _1-3 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl or C _3-6 cycloalkyl. ]
Or a hydrate or solvate thereof.

[Claim 3] R ⁸ and R ⁹ are the same or different and each represents a hydrogen atom, C _1-3 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl or C _3-6 cycloalkyl, Cycloalkyl-alkyl and cycloalkyl may be substituted with 1 to 5 fluorine atoms, where R ¹ , R ² , R ³ , R ⁴ and R ⁵ are all hydrogen atoms, R Any one of ⁸ and R ⁹ is a hydrogen atom,
Item 3. The medicine according to Item 2.

[Claim 4] R ¹ , R ² and R ³ are the same or different and are a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, trifluoromethyl, trifluoromethoxy, C _1-3 alkyl-S (O) _n. -Or cyano, and the alkyl-S (O) _n- may be substituted with 1 to 5 fluorine atoms,
Item 4. The medicine according to Item 2 or Item 3.

[Item 5] R ¹ , R ² and R ³ are the same or different and are a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, trifluoromethyl or trifluoromethoxy.
Item 4. The medicine according to Item 2 or Item 3.

[Item 6] The medicament according to any one of Items 2 to 5, wherein R ⁹ is a hydrogen atom.

[Item 7] R ⁴ and R ⁵ are the same or different and each is a hydrogen atom, a fluorine atom, a chlorine atom, C _1-3 alkyl, trifluoromethyl, or trifluoromethoxy.
Item 7. The medicine according to any one of Items 2 to 6.

[Item 8] R ⁶ and R ⁷ are the same or different and are a hydrogen atom, methyl, ethyl, hydroxyl group or C _1-3 alkoxy (provided that one is a hydroxyl group, the other is a hydroxyl group or C _1-3 alkoxy) is not),
Item 8. The medicine according to any one of Items 2 to 7.

[Item 9] R ¹ , R ² and R ³ are the same or different and are a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, trifluoromethyl or trifluoromethoxy,
R ⁴ and R ⁵ are the same or different and are a hydrogen atom, a fluorine atom, a chlorine atom, trifluoromethyl or trifluoromethoxy;
R ⁶ and R ⁷ are the same or different and are a hydrogen atom, methyl, hydroxyl group or methoxy (provided that one is a hydroxyl group, the other is not a hydroxyl group or methoxy),
R ⁸ is a hydrogen atom, methyl or ethyl,
R ⁹ is a hydrogen atom,
Item 3. The medicine according to Item 2.

[Item 10] The medicament according to Item 2 or Item 9, wherein R ¹ , R ² , R ³ , R ⁴ and R ⁵ are not all hydrogen atoms.

[Item 11] The medicament according to item 2, comprising a biphenylacetamide derivative selected from the following compounds or a hydrate or solvate thereof:
N, N-dimethyl-2- [4 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 3),
2- [3 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 4),
N-methyl-2- [3 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 5),
N-methyl-2- [2 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 7),
N-ethyl-2- [2 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 8),
2- (3 ′, 4′-difluorobiphenyl-2-yl) acetamide (Example 21),
2- (4′-fluorobiphenyl-2-yl) acetamide (Example 22),
2- (4′-fluorobiphenyl-2-yl) -N-methylacetamide (Example 23),
2- (3′-fluorobiphenyl-2-yl) -N-methylacetamide (Example 26),
2- (2′-fluorobiphenyl-2-yl) -N-methylacetamide (Example 28),
2- (2′-fluorobiphenyl-2-yl) -N, N-dimethylacetamide (Example 30),
N-methyl-2- (3′-methylbiphenyl-2-yl) -acetamide (Example 31),
2- (5-fluorobiphenyl-2-yl) acetamide (Example 39),
2- (4-fluorobiphenyl-2-yl) -N-methylacetamide (Example 45),
2- (2 ′, 4-difluorobiphenyl-2-yl) acetamide (Example 46),
2- (2 ′, 4-difluorobiphenyl-2-yl) -N-methylacetamide (Example 47),
2- (3′-chloro-4-fluorobiphenyl-2-yl) acetamide (Example 48),
2- (4′-bromobiphenyl-2-yl) acetamide (Example 49),
2- (biphenyl-2-yl) acetamide (Example 50),
2- (3′-bromobiphenyl-2-yl) acetamide (Example 52),
2- (4′-bromobiphenyl-2-yl) -N-methylacetamide (Example 53),
2- (biphenyl-2-yl) -N-methylacetamide (Example 54),
2- (biphenyl-2-yl) propanamide (Example 56),
2- (2′-fluorobiphenyl-2-yl) -N-methylpropanamide (Example 58),
2- (biphenyl-2-yl) -2-hydroxyacetamide (Example 59),
2- (2′-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 60),
2- (biphenyl-2-yl) -2-methoxyacetamide (Example 61),
2- (biphenyl-2-yl) -2-methoxy-N-methylacetamide (Example 62),
2- (biphenyl-2-yl) -2-methoxy-N, N-dimethylacetamide (Example 63),
2- (2 ′, 3 ′, 5′-trichlorobiphenyl-2-yl) acetamide (Example 64),
2- (4′-chloro-2′-fluorobiphenyl-2-yl) acetamide (Example 68),
2- [3′-fluoro-4 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide (Example 70),
2- [3′-fluoro-5 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 73),
2- [4′-chloro-3 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 75),
2- [4 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide (Example 76),
2- (2 ′, 4′-dichlorobiphenyl-2-yl) acetamide (Example 78),
2- [3 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide (Example 79),
2- [2′-fluoro-5 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 83),
2- [2′-chloro-4 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 84),
2- (2′-chloro-3′-fluorobiphenyl-2-yl) acetamide (Example 86),
2- (5′-chloro-2′-fluorobiphenyl-2-yl) acetamide (Example 87),
2- (2 ′, 3 ′, 4′-trifluorobiphenyl-2-yl) acetamide (Example 89),
2- [2′-fluoro-5 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide (Example 93),
2- (2 ′, 5′-dichlorobiphenyl-2-yl) acetamide (Example 95),
N-methyl-2- [3 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide (Example 99),
2- (2′-fluoro-5-nitrobiphenyl-2-yl) acetamide (Example 113),
2- (3-fluorobiphenyl-2-yl) acetamide (Example 118),
2- (3-fluorobiphenyl-2-yl) -N-methylacetamide (Example 119),
2- (5-chlorobiphenyl-2-yl) -N-methylacetamide (Example 124),
2- (5-chloro-2'-fluorobiphenyl-2-yl) acetamide (Example 125),
2- (5-chloro-2'-fluorobiphenyl-2-yl) -N-methylacetamide (Example 126),
2- [4-Chloro-4 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 142),
2- [3′-fluoro-5- (trifluoromethyl) biphenyl-2-yl] acetamide (Example 149),
2- (3 ′, 5′-dichloro-5-fluorobiphenyl-2-yl) acetamide (Example 150),
2- (3 ′, 5′-difluorobiphenyl-2-yl) acetamide (Example 153),
1- (2′-fluorobiphenyl-2-yl) -N-methylcyclopropanecarboxamide (Example 157),
1- (3′-fluorobiphenyl-2-yl) -N-methylcyclopropanecarboxamide (Example 159),
2-fluoro-2- (3′-fluorobiphenyl-2-yl) acetamide (Example 160),
2-fluoro-2- (2′-fluorobiphenyl-2-yl) -N-methylacetamide (Example 165),
2-fluoro-2- (4′-fluorobiphenyl-2-yl) -N-methylacetamide (Example 166),
2- (3′-chlorobiphenyl-2-yl) -2-fluoroacetamide (Example 167),
2,2-difluoro-2- (3′-fluorobiphenyl-2-yl) acetamide (Example 170),
2- (3′-chlorobiphenyl-2-yl) -2,2-difluoroacetamide (Example 171),
2- (biphenyl-2-yl) -2,2-difluoroacetamide (Example 174),
2- (3′-fluorobiphenyl-2-yl) propanamide (Example 175),
2- (5-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 181),
2- (3 ′, 5-difluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 182),
2- (3 ′, 5′-dichloro-5-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 184),
2- (3 ′, 4-difluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 188),
2- (3 ′, 5′-dichloro-4-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 189),
2- (5′-chloro-2′-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 194),
2- (2′-fluorobiphenyl-2-yl) -2-methoxyacetamide (Example 200),
2- (2′-fluorobiphenyl-2-yl) -2-methoxy-N-methylacetamide (Example 201),
2- (2′-fluorobiphenyl-2-yl) -2-methoxy-N, N-dimethylacetamide (Example 202),
2- (4′-fluorobiphenyl-2-yl) -2-methoxyacetamide (Example 203),
2- (4′-fluorobiphenyl-2-yl) -2-methoxy-N, N-dimethylacetamide (Example 205) and 2- (3′-chlorobiphenyl-2-yl) -2-methoxyacetamide ( Example 206).

[Item 12] The medicament according to item 2, comprising a biphenylacetamide derivative selected from the following compounds or a hydrate or solvate thereof:
2- (2′-fluorobiphenyl-2-yl) acetamide (Example 1),
N-methyl-2- [4 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 2),
2- (3′-chlorobiphenyl-2-yl) acetamide (Example 13),
2- (2′-chlorobiphenyl-2-yl) acetamide (Example 16),
2- (2 ′, 3′-difluorobiphenyl-2-yl) acetamide (Example 20),
2- (3′-fluorobiphenyl-2-yl) acetamide (Example 25),
2- (2 ′, 5-difluorobiphenyl-2-yl) acetamide (Example 41),
2- (4-fluorobiphenyl-2-yl) acetamide (Example 44),
2- (biphenyl-2-yl) -N-methylpropanamide (Example 57),
2- (biphenyl-2-yl) -2-hydroxyacetamide (Example 59),
2- (2′-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 60),
2- (2 ′, 3 ′, 5′-trifluorobiphenyl-2-yl) acetamide (Example 67),
2- (3 ′, 5′-dichlorobiphenyl-2-yl) acetamide (Example 71),
2- (3′-chloro-5′-fluorobiphenyl-2-yl) acetamide (Example 80),
2- (2′-chloro-5′-fluorobiphenyl-2-yl) acetamide (Example 88),
2- (3 ′, 4 ′, 5′-trifluorobiphenyl-2-yl) acetamide (Example 90),
2- [5′-chloro-2 ′-(trifluoromethyl) biphenyl-2-yl] acetamide (Example 91),
2- (4,4′-dichlorobiphenyl-2-yl) acetamide (Example 109),
2- (4,4′-difluorobiphenyl-2-yl) acetamide (Example 114),
2- (4,4′-difluorobiphenyl-2-yl) -N-methylacetamide (Example 115),
2- (3,3′-difluorobiphenyl-2-yl) acetamide (Example 140),
2- (2 ′, 5′-difluorobiphenyl-2-yl) acetamide (Example 152),
2- (biphenyl-2-yl) -2-fluoroacetamide (Example 162),
2-fluoro-2- (2′-fluorobiphenyl-2-yl) acetamide (Example 164),
2- (3′-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 178),
2- (3 ′, 5′-dichlorobiphenyl-2-yl) -2-hydroxyacetamide (Example 183),
2- (2′-chloro-5′-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 185),
2- (4-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 186),
2- (2′-chlorobiphenyl-2-yl) -2-hydroxyacetamide (Example 190),
2- (3′-chloro-5′-fluorobiphenyl-2-yl) -2-hydroxyacetamide (Example 191) and 2-hydroxy-2- (3 ′, 4 ′, 5′-trifluorobiphenyl- 2-yl) acetamide (Example 193).

  [Item 13] A pharmaceutical composition comprising the pharmaceutical according to any one of Items 1 to 12, and a pharmaceutically acceptable carrier.

  [Item 14] The medicament according to any one of Items 1 to 12, which is an antiepileptic drug or a mood stabilizer for bipolar disorder.

  [Item 15] The medicament according to any one of Items 1 to 12, which is a therapeutic or prophylactic agent for epilepsy and / or bipolar disorder.

Preferable specific examples of R ^{1 to} R ⁹ and n in the compound of formula (I) in Item 2 include the following.
R ^{1 to} R ³ are the same or different and are preferably a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, trifluoromethyl or trifluoromethoxy, more preferably the same or different, a hydrogen atom, a fluorine atom, chlorine An atom, trifluoromethyl or trifluoromethoxy, or the same or different, a hydrogen atom, a fluorine atom, or a chlorine atom;
R ⁴ and R ⁵ are the same or different and are preferably a hydrogen atom, a fluorine atom, a chlorine atom, trifluoromethyl or trifluoromethoxy, more preferably the same or different, a hydrogen atom, a fluorine atom or a chlorine atom. Yes, or both are hydrogen atoms.
R ⁶ and R ⁷ are the same or different and are preferably a hydrogen atom, fluorine atom, methyl, hydroxyl group or methoxy, more preferably the same or different, a hydrogen atom, methyl, hydroxyl group or methoxy, or the same or different. A hydrogen atom or a hydroxyl group, or both are hydrogen atoms.
R ⁸ is preferably a hydrogen atom, methyl or ethyl, and R ⁹ is preferably a hydrogen atom. More preferably, R ⁸ is a hydrogen atom or methyl, and R ⁹ is a hydrogen atom.
n is preferably 2.
Preferable specific examples of R ^{1 to} R ⁹ and n described above may limit the compounds of the above-mentioned items by one or any combination thereof, and the compounds of the formula (I) limited by these may also be used. This is one aspect of the present invention.

  The compounds according to the present invention are equally strong and anticonvulsant in any of the animal models used for the evaluation of antiepileptic drugs, so that antiepileptic drugs exhibiting a broad therapeutic spectrum (eg simple partial seizures, complex seizures). Prophylaxis against general seizures such as partial seizures and partial seizures such as generalized seizures, absence seizures, myoclonic seizures, clonic seizures, tonic seizures, tonic clonic seizures, weakness seizures, West syndrome and Lennox-Gastaut syndrome And / or therapeutic agent). The group of compounds of the present invention is also expected as a prophylactic and / or therapeutic agent for intractable epileptic seizures where conventional drug treatment is not successful. In addition, the compound according to the present invention exhibits a pathological improvement effect at a dose equivalent to a dose showing anticonvulsant activity in a model animal in a manic state and a depressed state, which is a pathological background of bipolar disorder. Expected to be a mood stabilizer for sexual disorders.

  Since the compounds according to the present invention may exist in the form of hydrates and / or solvates, these hydrates and / or solvates are also included in the compounds according to the present invention.

  In addition, the compounds according to the present invention may have one or more asymmetric carbon atoms and may cause geometric isomerism and axial chirality, and therefore exist as several stereoisomers. Sometimes. In the present invention, these stereoisomers, mixtures thereof and racemates are included in the compounds represented by formula (A) and formula (I) of the present invention.

The substitution position of R ¹ , R ² , R ³ , R ^a and R ^b in the compound of the formula (A) of the present invention is any carbon atom of 5 substitutable carbon atoms on the benzene ring to which they are bonded. They are bonded one by one, and the substitution positions of R ⁴ , R ⁵ , R ^c and R ^d are bonded one by one to any of the four substitutable carbon atoms on the benzene ring to which they are bonded. .

On the other hand, the substitution position of R ¹ , R ² and R ³ in the compound of the formula (I) of the present invention is any carbon atom among the five substitutable carbon atoms on the benzene ring to which they are bonded. 1 to 3 and R ⁴ and R ⁵ are substituted at one of any two of the four substitutable carbon atoms on the benzene ring to which they are bonded. Join one by one.
The substitution position numbers of R ¹ , R ² and R ³ in the compound of the formula (I) of the present invention are represented by the following formula (I ′). For example, any two groups of R ¹ , R ² and R ³ are 2′-methyl and 3′-methyl, which means that two methyl groups are present at the 2 ′ and 3 ′ positions in the following formula (I ′). Means replacing.

Next, terms used in this specification will be described below.
“Alkyl” means a linear or branched saturated hydrocarbon. For example, “C _1-3 alkyl” or “C _1-6 alkyl” has 1 to 3 or 1 carbon atoms. Each means ~ 6 groups. Specific examples thereof include methyl, ethyl, propyl, isopropyl and the like in the case of “C _1-3 alkyl”, and in the case of “C _1-6 alkyl”, in addition to the above, butyl, isobutyl, s- Examples include butyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl and the like.

“C _3-6 cycloalkyl” means a monocyclic saturated hydrocarbon having 3 to 6 carbon atoms. Specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

“C _3-7 cycloalkyl-C _1-3 alkyl” is a monocyclic saturated hydrocarbon having 3 to 7 carbon atoms, a straight or branched saturated hydrocarbon having 1 to 3 carbon atoms. An alkyl group bonded to any carbon atom of Specific examples thereof include cyclopropylmethyl, cyclobutylmethyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylpropyl, 2-cyclopropylpropyl, 1-cyclobutylethyl, 2-cyclobutylethyl, Examples include cyclopentylmethyl and cyclohexylmethyl.

“C _1-6 alkoxy” means a linear or branched alkoxy having 1 to 6 carbon atoms. Specific examples thereof include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, t-butoxy, pentyloxy, hexyloxy and the like.

“C _1-6 alkoxy substituted with 1 to 3 fluorine atoms” means one to three arbitrary hydrogen atoms of the above alkoxy substituted with fluorine atoms. Specific examples include difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 3,3,3-trifluoropropoxy, 4-fluorobutoxy, 4,4,4-trifluorobutoxy and the like. .

“C _1-6 alkyl-S (O) _n —” means a —S (O) _n — group to which a linear or branched alkyl having 1 to 6 carbon atoms is bonded. Here, when n is 0, alkylthio (eg, methylthio, ethylthio, etc.), when n is 1, alkylsulfinyl (eg, methylsulfinyl, ethylsulfinyl, etc.), when n is 2, alkylsulfonyl (eg, methane) Sulfonyl, ethanesulfonyl, etc.).

Alkyl (including methyl and ethyl) optionally substituted with 1 to 5 fluorine atoms, alkyl-S (O) _n- , alkoxy, cycloalkyl and cycloalkyl-alkyl are alkyl, alkoxy, cyclo It means that 1 to 5 substitutable hydrogen atoms on any carbon of alkyl and cycloalkyl-alkyl are replaced by fluorine atoms, and specific examples thereof include trifluoromethyl, fluoroethyl, Examples include trifluoroethyl, trifluoromethanesulfonyl, trifluoromethoxy, 2-fluorocyclopropyl, (2-fluorocyclopropyl) methyl, and the like. When the alkyl has 1 carbon, the number of fluorine atoms that may be substituted is 3 or less.

R ^{1 to} R ³ , R ^a , and R ^b include a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, C _1-6 alkyl, C _1-6 alkoxy substituted with 1 to 3 fluorine atoms, C _1-6 alkyl-S (O) _n — or cyano may be mentioned (the alkyl or alkyl-S (O) _n — may be substituted with 1 to 5 fluorine atoms, and n is 0 Represents an integer of 2), preferably a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, trifluoromethyl, trifluoromethoxy, methylthio, methanesulfonyl or cyano. More preferably, a hydrogen atom, a fluorine atom, a chlorine atom, trifluoromethyl, trifluoromethoxy or cyano is mentioned, more preferably a hydrogen atom, a fluorine atom, a chlorine atom or trifluoromethyl is mentioned, and particularly preferably, Examples thereof include a hydrogen atom, a fluorine atom or trifluoromethyl, or a hydrogen atom, a fluorine atom or a chlorine atom.

R ⁴ , R ⁵ , R ^c and R ^d are hydrogen atom, fluorine atom, chlorine atom, C _1-6 alkyl, C _1-6 alkoxy substituted with 1 to 3 fluorine atoms, C _{1- 6} alkyl-S (O) _n —, cyano or nitro may be mentioned (the alkyl or alkyl-S (O) _n — may be substituted with 1 to 5 fluorine atoms, and n is 0 to 0). 2), preferably a hydrogen atom, a fluorine atom, a chlorine atom, methyl, ethyl, trifluoromethyl, trifluoromethoxy, methylthio, methanesulfonyl or cyano. More preferably, a hydrogen atom, a fluorine atom, a chlorine atom, methyl, ethyl, trifluoromethyl, trifluoromethoxy or cyano is mentioned, and still more preferably a hydrogen atom, a fluorine atom, a chlorine atom, trifluoromethyl or trifluoromethoxy. Especially preferably, a hydrogen atom or a fluorine atom is mentioned.

R ⁶ and R ⁷ are each a hydrogen atom, a fluorine atom, methyl, ethyl, hydroxyl group or C _1-6 alkoxy, or C _6-6 cycloalkyl together with R ⁶ , R ⁷ and a carbon atom bonded thereto. (The methyl, ethyl, alkoxy and cycloalkyl may be substituted with 1 to 5 fluorine atoms), preferably a hydrogen atom, methyl, ethyl, hydroxyl group, methoxy or Ethoxy is mentioned. Especially preferably, a hydrogen atom, methyl, or a hydroxyl group is mentioned.

Examples of R ⁸ and R ⁹ include a hydrogen atom, C _1-6 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl, or C _3-6 cycloalkyl (the alkyl, cycloalkylalkyl, and cycloalkyl include , Optionally substituted with 1 to 5 fluorine atoms). R ⁸ is preferably a hydrogen atom, methyl, ethyl or cyclopropyl. Particularly preferred is a hydrogen atom or methyl. R ⁹ is preferably a hydrogen atom, methyl or ethyl. Particularly preferred is a hydrogen atom or methyl.

  n may be an integer of 0 to 2, and preferably 0 or 2. Particularly preferably, 2 is mentioned.

  Epilepsy in the present invention is intended for chronic diseases in which cranial movements, consciousness, sensory abnormalities and behavioral abnormalities derived from excessive excitement of cranial nerve cells are intended, and simple partial seizures, complex partial seizures and secondary generalization General seizures such as partial seizures such as seizures, absence seizures, myoclonic seizures, clonic seizures, tonic seizures, tonic clonic seizures, weakness seizures, West syndrome and Lennox-Gastaut syndrome are included. In the present invention, the antiepileptic drug is intended to be a prophylactic and / or therapeutic drug for the above diseases, and the epilepsy treatment method is intended to be a preventive and / or therapeutic method for the above diseases.

  The bipolar disorder in the present invention means a disease that repeats a manic state and a depressive state to cause mood modulation, and the mood stabilizer for bipolar disorder in the present invention is a preventive and / or therapeutic agent for the above-mentioned diseases. Intentionally, a method for treating bipolar disorder intends a method for preventing and / or treating the above-mentioned diseases.

Note that the following abbreviations may be used to simplify the description in this specification. p-: para-, t-: tert-, s-: sec-, THF: tetrahydrofuran, DMF: N, N- dimethylformamide, DME: ethylene glycol dimethyl ether, DMSO: dimethylsulfoxide, CDCl _3: deuterated chloroform, DMSO- d ₆ : heavy dimethyl sulfoxide, TFA: trifluoroacetic acid, MeCN: acetonitrile

The compound of the formula (I) of the present invention can be synthesized by the following procedure. The compound of formula (A) can also be synthesized and purified by introducing the substituents R ^{a to} R ^d into the starting material and performing the same procedure as described below.

[Production Method 1]
The compound of formula (I) wherein R ⁶ and R ⁷ are groups other than hydroxyl groups [compound of formula (Ia) below] can be produced by the following production method.

(Wherein R ^{1 to} R ⁵ , R ⁸ and R ⁹ are the same as defined in item 1, and R ⁶¹ and R ⁷¹ are the same or different and represent a hydrogen atom, a fluorine atom, methyl, ethyl or C _1- Represents ₆ alkoxy, or together with R ⁶¹ , R ⁷¹ and the carbon atom to which they are attached, constitutes a C _3-6 cycloalkyl.)
When compound (II) is amidated, compound (Ia) is obtained.

  The amidation reaction of compound (II) can be performed according to a conventional method. For example, this reaction is achieved by converting compound (II) into a reactive derivative (for example, a lower alkyl ester, an active ester, an acid anhydride, an acid halide, etc.) and reacting with ammonia or various amines. Specific examples of the active ester include p-nitrophenyl ester, N-hydroxysuccinimide ester, pentafluorophenyl ester and the like. Specific examples of the acid anhydride include mixed acid anhydrides with ethyl chlorocarbonate, isobutyl chlorocarbonate, isovaleric acid, pivalic acid and the like.

  Compound (Ia) can also be produced by reacting compound (II) with ammonia or various amines in the presence of a condensing agent. Specific examples of the condensing agent include N, N′-dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide monohydrochloride, N, N′-carbonyldiimidazole, benzotriazol-1-yl -Oxytris (pyrrolidino) phosphonium- hexafluorophosphate etc. are mentioned. These condensing agents can be used alone or in combination with these condensing agents and peptide synthesis reagents such as N-hydroxysuccinimide and N-hydroxybenzotriazole.

  The reaction of compound (II) with ammonia or various amines is carried out in a solvent or without a solvent. Specific examples of the solvent should be selected according to the type of raw material compound, etc., and include, for example, toluene, THF, dioxane, DME, dichloromethane, chloroform, ethyl acetate, acetone, acetonitrile, DMF, DMSO, etc. Alternatively, it can be used as a mixed solvent. Ammonia or various amines may be used in the form of an acid addition salt such as an aqueous solution or hydrochloride, and a free base may be generated in the reaction system. This reaction is usually carried out in the presence of a base. Specific examples of the base used include inorganic bases such as potassium carbonate and sodium hydrogen carbonate, triethylamine, ethyldiisopropylamine, N-methylmorpholine, pyridine. And organic bases such as 4-dimethylaminopyridine. While the reaction temperature varies depending on the kind of raw material compound used, it is generally about −30 ° C. to about 150 ° C., preferably about −10 ° C. to about 70 ° C.

[Production Method 2]
The compound of formula (I) wherein at least one of R ⁶ and R ⁷ is a hydroxyl group [compound of the following formula (1b)] can be produced by the following production method.

(In the formula, R ^{1 to} R ⁵ , R ⁸ and R ⁹ are the same as defined in item 1; one of R ⁶² and R ⁷² is a hydroxyl group, and the other is a hydrogen atom, methyl or ethyl; And R ¹⁰ is C _1-6 alkyl.)
When compound (III) is reacted with ammonia or various amines, compound (Ib) is obtained.

  The reaction of compound (III) with ammonia or various amines is carried out in a solvent or without a solvent. Specific examples of the solvent should be selected according to the type of the raw material compound, etc., for example, toluene, THF, dioxane, DME, dichloromethane, chloroform, ethyl acetate, acetone, acetonitrile, DMF, DMSO, methanol, ethanol, ethylene A glycol etc. are mentioned, It can use individually or as a mixed solvent. While the reaction temperature varies depending on the kind of raw material compound used, it is generally about −30 ° C. to about 150 ° C., preferably about −10 ° C. to about 70 ° C.

[Production Method 3]
The compound of formula (I) wherein R ⁶ and R ⁷ are groups other than hydroxyl groups [compound of the following formula (Ic)] can be produced by the following production method.

(Wherein R ^{1 to} R ⁵ , R ⁸ and R ⁹ are the same as defined in item 1, and R ⁶¹ and R ⁷¹ are the same or different and represent a hydrogen atom, a fluorine atom, methyl, ethyl or C _{1- 6} represents alkoxy, or together with R ⁶¹ , R ⁷¹ and the carbon atom bonded thereto, forms C _3-6 cycloalkyl, and X is a chlorine atom, bromine atom, iodine atom or triflate (CF ₃ SO _3- ).)
When compound (VI) is coupled with various substituted phenylboronic acids, compound (Ic) is obtained.

Compound (Ic) is obtained by mixing compound (VI) with a boron reagent such as various substituted phenylboronic acids [PhB (OH) ₂ ], an organometallic reagent such as various substituted phenyl zinc chlorides, and the like in a suitable solvent. It can be obtained by performing a cross-coupling reaction under a transition metal catalyst such as a palladium catalyst typified by phosphine palladium. In these coupling reactions, in addition to the above reagents, inorganic bases such as alkali metal carbonates (for example, sodium carbonate, potassium carbonate, cesium carbonate, etc.) and potassium phosphate, organic bases such as triethylamine, diisopropylethylamine, and chloride It can also be carried out in the presence of an inorganic salt such as lithium or cesium fluoride.

  Various boron reagents or organometallic reagents used in the coupling reaction with compound (VI) are commercially available, or are prepared from commercially available reagents according to known methods. Specific examples of the solvent should be selected according to the type of raw material compound and the type of reagent used. For example, toluene, THF, dioxane, DME, ethyl acetate, acetone, acetonitrile, DMF or methanol, ethanol, isopropanol, t -Alcohols, such as butanol, water, etc. are mentioned, It can use individually or as a mixed solvent. While the reaction temperature varies depending on the raw material compound and the type of reagent used, it is generally 0 to 200 ° C, preferably 60 to 150 ° C.

  The compounds of the formulas (Ia), (Ib) and (Ic) produced by the above production methods 1, 2, and 3 can be isolated and purified by usual methods such as chromatography and recrystallization.

  Next, the raw material compounds used in the above production methods 1, 2, and 3 can be produced by the following method.

  Compound (II) used in Production Method 1 is produced according to the method shown by the following reaction formula.

(Wherein R ^{1 to} R ⁵ , R ⁶¹ and R ⁷¹ are the same as defined in Production Method 1, R ¹⁰ is C _1-6 alkyl, and X is a chlorine atom, bromine atom, iodine atom or trif. Rate (CF ₃ SO _3- ).)

[Step 1]: Compound (V) is obtained by esterifying compound (IV).
The esterification reaction in step 1 can be performed according to a conventional method. For example, this reaction is carried out by contacting compound (IV) with various alcohols or alkyl halides in an appropriate solvent under acidic or basic conditions. Alternatively, it can also be synthesized by reacting compound (IV) with a diazo compound such as diazomethane or trimethylsilyldiazomethane. Specific examples of the solvent should be selected according to the type of raw material compound, etc., and include, for example, alcohols such as THF, dioxane, DME, acetone, acetonitrile, DMF, toluene or methanol, ethanol, isopropanol, etc. Alternatively, it can be used as a mixed solvent. Specific examples of the acid used include mineral acids such as hydrochloric acid, sulfuric acid and hydrofluoric acid, and organic acids such as trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid and p-toluenesulfonic acid. Specific examples of the base used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkoxy alkali metals such as t-butoxy potassium, sodium carbonate, potassium carbonate and lithium carbonate. An alkali metal carbonate is mentioned. While the reaction temperature varies depending on the raw material compound and the type of reagent used, it is generally 0 to 150 ° C, preferably 20 to 100 ° C.

[Step 2]: Compound (IIIa) is compound (V) and a boron reagent such as various substituted phenylboronic acids [PhB (OH) ₂ ], an organometallic reagent such as various substituted phenyl zinc chlorides, etc. in an appropriate solvent. Can be obtained by performing a cross-coupling reaction under a transition metal catalyst such as a palladium catalyst typified by tetrakistriphenylphosphine palladium. In these coupling reactions, in addition to the above reagents, inorganic bases such as alkali metal carbonates (for example, sodium carbonate, potassium carbonate, cesium carbonate, etc.) and potassium phosphate, organic bases such as triethylamine, diisopropylethylamine, and chloride In some cases, the reaction is carried out in the presence of an inorganic salt such as lithium or cesium fluoride. The compound (IIIa) in which R ⁶¹ and R ⁷¹ are fluorine can also be synthesized using a known method or a method analogous thereto. (WO2009013963, US2004254166, Tetrahedron Letters, 27, 6103-6106 (1986))

  Various boron reagents or organometallic reagents used in Step 2 are commercially available, or are prepared from commercially available reagents according to a known method. Specific examples of the solvent should be selected according to the type of raw material compound and the type of reagent used. For example, toluene, THF, dioxane, DME, ethyl acetate, acetone, acetonitrile, DMF or methanol, ethanol, isopropanol, t -Alcohols, such as butanol, water, etc. are mentioned, It can use individually or as a mixed solvent. While the reaction temperature varies depending on the raw material compound and the type of reagent used, it is generally 0 to 200 ° C, preferably 60 to 150 ° C.

[Step 3]: Compound (II) is obtained by hydrolyzing compound (IIIa).
The hydrolysis reaction in step 3 can be performed according to a conventional method. For example, this reaction is carried out by contacting compound (IIIa) with water in an appropriate solvent under acidic or basic conditions. Specific examples of the solvent should be selected according to the kind of the raw material compound, and include, for example, THF, dioxane, DME, acetone, acetonitrile, DMF, DMSO or alcohols such as methanol, ethanol, isopropanol, and water. Can be used alone or as a mixed solvent. Specific examples of the acid used include mineral acids such as hydrochloric acid and sulfuric acid. Specific examples of the base used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkoxy alkali metals such as t-butoxy potassium, sodium carbonate, potassium carbonate and lithium carbonate. An alkali metal carbonate is mentioned. While the reaction temperature varies depending on the raw material compound and the type of reagent used, it is generally 0 to 150 ° C, preferably 20 to 100 ° C.
In this production method, compound (II) can also be produced by subjecting compound (IV) to the same reaction as in step 1 without passing through steps 2 and 3.

  Compound (III) used in Production Method 2 is produced in the same manner as in the method represented by the above reaction formula.

The compound (IIIa) [compound of the following formula (IIIc)] in which R ⁶¹ and / or R ⁷¹ used in the above method is C _1-6 alkyl or a fluorine atom is produced according to the method shown by the following reaction formula.

(In the formula, R ^{1 to} R ⁵ are the same as defined in item 1, and at least one of R ⁶³ and R ⁷³ is a hydrogen atom or a hydroxyl group, and when only one is a hydrogen atom or a hydroxyl group, the other is Is the same as the definition of R ⁶ and R ^{7 in} item 1, at least one of R ⁶⁴ and R ⁷⁴ is C _1-6 alkyl or fluorine, and the other is the definition of R ⁶ and R ^{7 in} item 1. And R ¹⁰ is C _1-6 alkyl.)
When compound (IIIb) is alkylated or fluorinated, compound (IIIc) is obtained.

  The alkylation or fluorination reaction can be performed according to a conventional method. For example, this reaction may be carried out by subjecting compound (IIIb) and alkyl halide, dimethyl sulfate, (diethylamino) sulfur trifluoride, bis (2-methoxyethyl) aminosulfur trifluoride, etc. under an appropriate solvent under neutral or basic conditions. This is done by contacting them. Specific examples of the solvent should be selected according to the type of raw material compound, etc. For example, alcohols such as toluene, hexane, diethyl ether, THF, dioxane, DME, acetone, acetonitrile, DMF or methanol, ethanol, isopropanol, etc. And water, etc., can be used alone or as a mixed solvent. Specific examples of the base used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkali metal hydrides such as sodium hydride and potassium hydride, sodium methoxide, sodium ethoxide, Alkoxy alkali metals such as t-butoxy potassium, alkali carbonates such as sodium carbonate, potassium carbonate and lithium carbonate, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, etc. Organic bases such as metal amide, pyridine, triethylamine, 4-dimethylaminopyridine and the like can be mentioned. While the reaction temperature varies depending on the raw material compound used and the type of reagent, etc., it is generally -78 to 150 ° C, preferably -20 to 70 ° C.

  Compound (IIIb) is produced by a method similar to the production method of compound (IIIa). Compound (II) can also be produced from compound (IIIc) by a method similar to the method of deriving compound (IIIa) to compound (II) (step 3). Compound (IV) is a commercially available compound, or can be produced from a known compound according to a known method.

  Compound (VI) used in Production Method 3 can be obtained, for example, by subjecting Compound (IV) to an amidation reaction in Production Method 1 or 2.

  The compound of the formula (I) produced | generated by each said manufacturing method can be isolated and refine | purified by conventional methods, such as a chromatography, recrystallization, and reprecipitation. In addition, when the compound of formula (I) is a racemate, according to a conventional method such as an optical resolution method by chromatography using an optically active column, a preferential crystallization method, a diastereomer method, etc. And can be separated and purified.

  The novel biphenylacetamide derivative of the present invention is useful as an antiepileptic drug as described later. The administration route of the compound according to the present invention may be any of oral administration, parenteral administration or rectal administration, and the daily dose varies depending on the type of compound, administration method, patient symptom / age and the like. For example, in the case of oral administration, it is usually 1 to 200 mg, preferably 5 to 100 mg, more preferably 10 to 70 mg, and more preferably 10 to 70 mg, and more preferably 500 to 5000 mg, more preferably 500 per kg body weight of a mammal. ˜3000 mg can be administered in 1 to several divided doses. In the case of parenteral administration such as intravenous injection, it is usually 0.1 to 100 mg, preferably 1 to 10 mg, more preferably 4 to 5 mg, and more preferably 50 to 1000 mg, preferably 100 to 400 mg per 1 kg body weight of a mammal, More preferably, 200-300 mg can be administered.

  The compound according to the present invention is usually administered in the form of a preparation prepared by mixing with a pharmaceutical carrier when used for pharmaceutical use as described above. As the pharmaceutical carrier, a non-toxic substance that is commonly used in the pharmaceutical field and does not react with the compound according to the present invention is used. Specifically, for example, citric acid, glutamic acid, glycine, lactose, inositol, glucose, mannitol, dextran, sorbitol, cyclodextrin, starch, partially pregelatinized starch, sucrose, methyl paraoxybenzoate, propyl paraoxybenzoate, and aluminum metasilicate Magnesium sulfate, synthetic aluminum silicate, crystalline cellulose, sodium carboxymethylcellulose, hydroxypropyl starch, carboxymethylcellulose calcium, ion exchange resin, methylcellulose, gelatin, gum arabic, pullulan, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose , Polyvinylpyrrolidone, polyvinyl alcohol, alginic acid, sodium alginate Light anhydrous silicic acid, magnesium stearate, talc, tragacanth, bentonite, bee gum, carboxyvinyl polymer, titanium oxide, sorbitan fatty acid ester, sodium lauryl sulfate, glycerin, fatty acid glycerin ester, purified lanolin, glycerogelatin, polysorbate, macrogol, vegetable oil Wax, propylene glycol, ethanol, benzyl alcohol, sodium chloride, sodium hydroxide, hydrochloric acid, water and the like.

  Examples of the dosage form include tablets, capsules, granules, powders, syrups, suspensions, injections, suppositories, eye drops, ointments, coatings, patches, inhalants and the like. These preparations can be prepared according to a conventional method. In the case of a liquid preparation, it may be dissolved or suspended in water or other appropriate medium at the time of use. Tablets and granules may be coated by a known method. In addition, these formulations may contain other therapeutically valuable ingredients.

Hereinafter, the present invention will be described more specifically with reference to reference examples, examples, and test examples, but these examples do not limit the present invention. The compound was identified by elemental analysis, mass spectrum, high performance liquid chromatography / mass spectrometer; LCMS, IR spectrum, NMR spectrum (400 MHz ¹ H-NMR, etc.), high performance liquid chromatography (HPLC) and the like.

  In order to simplify the description of the specification, the following abbreviations may be used in the examples and tables in the examples.

  As symbols used in NMR, s means a single line, d means a double line, t means a triple line, q means a quadruple line, m means a multiple line, and br means a broad line.

High-performance liquid chromatograph / mass spectrometer; LCMS measurement conditions are as follows, and the observed mass spectrometry value [MS (m / z)] is represented by MH ⁺ and the retention time is represented by Rt (min). min indicates minutes.
Detection equipment: Agilent 1100 series for API series (Applied Biosystems)
HPLC: API150EX LC / MS system (Applied Biosystems)
Column: YMC CombiScreen ODS-A (S-5 μM, 12 nm, 4.6 × 50 mm)
Condition A (Hereinafter, what is not particularly described in the examples is measurement under these conditions.)
Solvent: Liquid A: 0.05% TFA / H ₂ O, Liquid B: 0.035% TFA / MeCN
Gradient Condition: 0.0-0.5 min A 90%, 0.5-4.2 min Linear gradient from A 90% to 1%, 4.2-4.4 min Linear gradient from A 1% to 99%
Flow rate: 3.5 mL / min
UV: 220 nm
Condition B (Hereinafter, those marked with * in the examples are measured under these conditions.)
Solvent: Liquid A: 0.05% TFA / H2O, Liquid B: 0.035% TFA / MeOH
Gradient Condition: 0.0-1.0 min A 60%, 1.0-4.7 min Linear gradient from A 60% to 1%, 4.7-5.7 min Linear gradient from A 1% to 60%
Flow rate: 1.8 mL / min
UV: 220 nm

Reference example 1:
(2'-Fluorobiphenyl-2-yl) acetic acid

[Step 1] To a solution of 2-bromophenylacetic acid (12.8 g) and potassium carbonate (16.4 g) in DMF (50 ml), a solution of ethyl iodide (5.7 ml) in DMF (20 ml) is added dropwise at 0 ° C. The mixture was warmed to room temperature and stirred overnight. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography to obtain ethyl (2-bromophenyl) acetate (13.3 g) as an oil.

[Step 2]: Ethyl (2-bromophenyl) acetate (4.01 g), 2-fluorophenylboronic acid (3.46 g), tetrakis (triphenylphosphine) palladium (0) (0.95 g), potassium carbonate ( 6.82 g) of dioxane-water (10: 1) (44 ml) was heated to reflux at 110 ° C. for 8 hours under a nitrogen stream. After completion of the reaction, the reaction mixture was cooled to room temperature, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography to obtain ethyl (2'-fluorobiphenyl-2-yl) acetate (3.87 g) as an oil.

[Step 3]: Ethyl (2′-fluorobiphenyl-2-yl) acetate (1.00 g) in THF (5.0 ml) was added to lithium hydroxide monohydrate (0.19 g) in water (5 0.0 ml) solution and methanol (5.0 ml) were added and stirred at room temperature for 12 hours. AMBERLITE (registered trademark) IR-120 PLUS (H) was added to the reaction solution to adjust the solution to pH 4, and then filtered to concentrate the filtrate. The precipitated crystals were collected by filtration to obtain (2′-fluorobiphenyl-2-yl) acetic acid (0.89 g) as crystals.
¹ H-NMR (CDCl ₃ ) δ: 3.57 (s, 2H), 7.13 (t, 1H), 7.18 (t, 1H), 7.23-7.28 (m, 3H), 7.34-7.40 (m, 3H).

Reference Example 2-26:
The corresponding starting materials were used and reacted and treated in the same manner as described in Reference Example 1 to obtain the compounds shown in Table 1.

Reference Example 27:
2- (biphenyl-2-yl) propanoic acid

[Step 1] Sodium hexamethyldisilazide (1.9 M THF solution) (7.2 ml) was added dropwise to a solution of ethyl biphenyl-2-yl acetate (2.50 g) in THF (25 ml) at −78 ° C. The mixture was stirred at the same temperature for 0.5 hour. Methyl iodide (0.78 ml) was added dropwise to the reaction solution, and the mixture was stirred at −40 ° C. for 2.5 hours. After completion of the reaction, a saturated aqueous sodium hydrogen carbonate solution was added and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel chromatography to give ethyl 2- (biphenyl-2-yl) propanoate (2.57 g).

[Step 2]: Ethyl 2- (biphenyl-2-yl) propanoate (1.20 g) in THF (5.0 ml) was added to lithium hydroxide monohydrate (0.24 g) in water (5.0 ml). ) Solution and methanol (5.0 ml) were added and stirred at room temperature for 12 hours. AMBERLITE (registered trademark) IR-120 PLUS (H) was added to adjust the solution to pH 4, followed by filtration, and the filtrate was concentrated. The precipitated crystals were collected by filtration to give 2- (biphenyl-2-yl) propanoic acid (1.03 g) as crystals.
¹ H-NMR (CDCl ₃ ) δ: 1.38 (d, 3H), 3.93 (q, 1H), 7.24-7.28 (m, 2H), 7.29 (dd, 1H), 7.34-7.45 (m, 7H).

Reference Example 28:
Methyl biphenyl-2-yl (hydroxy) acetate

[Step 1]: (2-Bromophenyl) (hydroxy) acetic acid (7.00 g) is dissolved in a mixture of toluene (20 ml) and methanol (20 ml), and trimethylsilyldiazomethane (2 mol / l hexane solution) (23 ml) is added dropwise. Then, it stirred at room temperature for 1 hour. After evaporating the solvent under reduced pressure, the residue was purified by silica gel column chromatography to obtain methyl (2-bromophenyl) (hydroxy) acetate (4.12 g) as an oil.

[Step 2]: Methyl (2-bromophenyl) (hydroxy) acetate (613 mg), phenylboronic acid (457 mg), [1,1′-bis (diphenylphosphino) ferrocene] palladium (II) dichloride dichloromethane complex (1 1) (204 mg) and a solution of potassium phosphate (1.59 g) in dioxane (10 ml) were heated to reflux overnight under a nitrogen stream. The reaction mixture was purified by silica gel column chromatography to give methyl biphenyl-2-yl (hydroxy) acetate (190 mg) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 3.37 (d, 1H), 3.71 (s, 3H), 5.25 (d, 1H), 7.30-7.34 (m, 1H), 7.39-7.45 (m, 8H).

Reference Example 29:
Methyl (2′-fluorobiphenyl-2-yl) (hydroxy) acetate was used in the same manner as in the method described in Reference Example 28, and the following compounds were obtained.

Reference Example 30:
Biphenyl-2-yl (methoxy) acetic acid

[Step 1] To a solution of methyl biphenyl-2-yl (hydroxy) acetate (4.79 g) and methyl iodide (2.5 ml) in DMF (50 ml) was added 1.11 g of sodium hydride under ice cooling, The mixture was stirred for 30 minutes and further stirred at room temperature for 1 hour. The reaction solution was added to ice water, extracted with ethyl acetate, washed with saturated brine, and then dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was purified by silica gel column chromatography to obtain methyl biphenyl-2-yl (methoxy) acetate (3.64 g) as crystals.

[Step 2]: Methyl biphenyl-2-yl (methoxy) acetate (1.61 g) in THF (10 ml) solution, lithium hydroxide monohydrate (0.49 g) in water (10 ml) and methanol ( 10 ml) was added and stirred at room temperature overnight. A 10% aqueous citric acid solution was added to adjust the pH of the reaction solution to 3, followed by extraction with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give biphenyl-2-yl (methoxy) acetic acid (1.52 g) as an oil.
¹ H-NMR (CDCl ₃ ) δ: 3.19 (s, 3H), 4.94 (s, 1H), 7.31-7.35 (m, 1H), 7.40-7.51 (m , 8H).

Reference Example 31:
1- (biphenyl-2-yl) cyclopropanecarboxylic acid

[Step 1]: 1- (2-Bromophenyl) cyclopropanecarboxylic acid (2.00 g) and phenylboronic acid (1.52 g) are dissolved in N, N-dimethylformamide (48 ml), and [1,1 ′ -Bis (diphenylphosphino) ferrocene] palladium (II) dichloride / dichloromethane complex (0.34 g), 2N-aqueous sodium carbonate solution (12 ml) was added, and the mixture was purged with nitrogen, followed by stirring for 40 hours under heating at 80 ° C. After the solvent was distilled off under reduced pressure, 2N-aqueous sodium hydroxide solution was added to the residue, and insoluble matters were removed by celite filtration. The filtrate was washed with ethyl acetate, and concentrated hydrochloric acid was added to adjust to pH 1. The mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was purified by silica gel column chromatography to obtain 1- (biphenyl-2-yl) cyclopropanecarboxylic acid (1.58 g) as white crystals.
¹ H-NMR (DMSO-d ₆ ) δ: 0.77 (br, 2H), 1.20 (br, 2H), 7.19-7.21 (m, 1H), 7.30-7.44 (M, 8H).

Reference Examples 32 and 33:
The corresponding starting materials were used and reacted and treated in the same manner as described in Reference Example 31 to obtain the compounds shown in Table 2.

Reference Example 34:
Fluoro (3'-fluorobiphenyl-2-yl) acetic acid

[Step 1]: (3′-Fluorobiphenyl-2-yl) acetic acid ethyl ester (1.50 g) was dissolved in tetrahydrofuran (10 ml) under a nitrogen atmosphere, and lithium hexamethyldisilazide (1M toluene) was dissolved at −78 ° C. Solution) (6.4 ml) was added and stirred for 10 minutes. A solution of N-fluoro-N- (phenylsulfonyl) benzenesulfonamide (3.36 g) in tetrahydrofuran (10 ml) was added dropwise, and then returned to room temperature over 1 hour and stirred overnight. Saturated aqueous ammonium chloride solution was added, extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was purified by silica gel column chromatography to obtain ethyl fluoro (3′-fluorobiphenyl-2-yl) acetate (1.46 g) as a colorless oil.
¹ H-NMR (CDCl ₃ ) δ: 1.25 (t, 3H), 4.15-4.29 (m, 2H), 5.81 (d, 1H), 7.09-7.22 (m , 3H), 7.34-7.48 (m, 4H), 7.57-7.59 (m, 1H).

[Step 2]: Ethyl fluoro (3′-fluorobiphenyl-2-yl) acetate (1.46 g) was dissolved in tetrahydrofuran (10 ml), and lithium hydroxide monohydrate (0.67 g) in water (10 ml) ) Solution and methanol (10 ml) were added and stirred at room temperature for 6 hours. A 10% aqueous citric acid solution was added to adjust the reaction solution to pH 3, followed by extraction with ethyl acetate. After washing with saturated brine and drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure to obtain fluoro (3′-fluorobiphenyl-2-yl) acetic acid (1.32 g) as white crystals.
¹ H-NMR (CDCl ₃ ) δ: 5.88 (d, 1H), 7.09-7.17 (m, 2H), 7.19-7.22 (m, 1H), 7.34-7 .53 (m, 4H), 7.59-7.62 (m, 1H).

Reference Example 35:
Using the corresponding starting material compound for fluoro (biphenyl-2-yl) acetic acid , the reaction and treatment were carried out in the same manner as in the method described in Reference Example 34 to obtain the compounds shown below.

Reference Example 36:
Fluoro (2'-fluorobiphenyl-2-yl) acetic acid

[Step 1]: Methyl (2′-fluorobiphenyl-2-yl) hydroxyacetate (1.70 g) was dissolved in dichloromethane (20 ml), and [bis (2-methoxyethyl) -amino] sulfur trifluoro under ice-cooling. Lido (2.0 ml) was added and stirred at room temperature overnight. After washing with ice water and drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. Purification by silica gel column chromatography gave methyl fluoro (2′-fluorobiphenyl-2-yl) acetate (1.33 g) as a colorless oil.
¹ H-NMR (CDCl ₃ ) δ: 3.69 (s, 3H), 5.72 (d, 1H), 7.16-7.25 (m, 2H), 7.34-7.44 (m , 3H), 7.47-7.49 (m, 2H), 7.60 (br, 1H).

[Step 2]: Methyl fluoro (2′-fluorobiphenyl-2-yl) acetate (1.33 g) was dissolved in tetrahydrofuran (10 ml), and lithium hydroxide monohydrate (0.64 g) in water (10 ml) ) Solution and methanol (10 ml) were added and stirred at room temperature for 6 hours. 2N-hydrochloric acid was added to adjust to pH 3, followed by extraction with ethyl acetate. The extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give fluoro (2′-fluorobiphenyl-2-yl) acetic acid (1.33 g) as a colorless oil.
¹ H-NMR (CDCl ₃ ) δ: 5.76 (d, 1H), 7.15-7.23 (m, 2H), 7.37 (br, 3H), 7.49-7.50 (m , 2H), 7.62 (br, 1H).

Reference Example 37:
Using the corresponding starting material compound for fluoro (4′-fluorobiphenyl-2-yl) acetic acid , the reaction and treatment were carried out in the same manner as in the method described in Reference Example 36 to obtain the compound shown below.

Reference Example 38:
Fluoro (3'-chlorobiphenyl-2-yl) acetic acid

[Step 1]
Ethyl 2-bromophenyl-hydroxyacetate (1.74 g) was dissolved in dichloromethane (20 ml), and [bis (2-methoxyethyl) -amino] sulfur trifluoride (2.1 ml) was added under ice-cooling. Stir for 1 hour. After washing with ice water and drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. Purification by silica gel column chromatography gave ethyl 2-bromophenyl-fluoroacetate (1.20 g) as a colorless oil.
¹ H-NMR (CDCl ₃ ) δ: 1.27 (t, 3H), 4.18-4.36 (m, 2H), 6.20 (d, 1H), 7.24-7.30 (m , 1H), 7.35-7.40 (m, 1H), 7.49-7.52 (m, 1H), 7.60-7.64 (m, 1H).

[Step 2]: Ethyl 2-bromophenyl-fluoroacetate (1.20 g) and 3-chlorophenylboronic acid (1.08 g) are dissolved in 1,4-dioxane (20 ml), and tetrakis (triphenylphosphine) palladium ( 0.27 g), 3-chlorophenylboronic acid (1.08 g), potassium carbonate (1.91 g) and water (2 ml) were added, and the mixture was purged with nitrogen, followed by stirring overnight at 80 ° C. with heating. Water was added, the mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous magnesium sulfate. The residue was purified by silica gel column chromatography to give fluoro (3′-chlorobiphenyl-2-yl) acetic acid (540 mg) as a brown oil.
¹ H-NMR (CDCl ₃ ) δ: 5.86 (d, 1H), 7.31-7.50 (m, 7H), 7.59-7.61 (m, 1H).

Reference Example 39:
Biphenyl-2-yl (difluoro) acetic acid

[Step 1]:
Dissolve ethyl biphenyl-2-yl (difluoro) acetate (1.59 g) in tetrahydrofuran (10 ml), add lithium hydroxide monohydrate (0.72 g) in water (10 ml) and methanol (10 ml). Stir overnight at room temperature. A 10% aqueous citric acid solution was added to adjust the reaction solution to pH 3, followed by extraction with ethyl acetate. The extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give carboxylic acid (1.53 g) as a colorless oil.
¹ H-NMR (DMSO) δ: 7.21-7.24 (m, 2H), 7.28 (d, 1H), 7.37-7.39 (m, 3H), 7.54-7. 62 (m, 2H), 7.71-7.73 (m, 1H), 14.5 (br, 1H).

Reference Example 40:
(2'-Fluorobiphenyl-2-yl) difluoroacetic acid

[Step 1]: Ethyl (2′-fluorobiphenyl-2-yl) acetate (1.5 g) was dissolved in tetrahydrofuran (20 ml) under a nitrogen atmosphere, cooled to −78 ° C., and sodium hexamethyldisilazide. (1.06 M toluene solution) (12.1 ml) was added and stirred at that temperature for 20 minutes. A solution of N-fluoro-N- (phenylsulfonyl) benzenesulfonamide (4.03 g) in tetrahydrofuran (20 ml) was added dropwise at −78 ° C., then slowly returned to room temperature and stirred overnight. Saturated aqueous ammonium chloride solution was added for acidification, and water and ethyl acetate were added. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. Purification by silica gel column chromatography gave ethyl (2′-fluorobiphenyl-2-yl) difluoroacetate (973 mg) as a colorless oil.
¹ H-NMR (CDCl ₃ ) δ: 1.17 (t, 3H), 3.98-4.06 (m, 2H), 7.08-7.39 (m, 4H), 7.35-7 .41 (m, 1H), 7.50-7.56 (m, 2H), 7.80-7.84 (m, 1H).

[Step 2]: Ethyl (2′-fluorobiphenyl-2-yl) difluoroacetate (973 mg) was dissolved in tetrahydrofuran (5 ml), a solution of lithium hydroxide monohydrate (416 mg) in water (5 ml), methanol ( 5 ml) was added and stirred at room temperature for 6 hours. A 10% aqueous citric acid solution was added to adjust the pH to 3, followed by extraction with ethyl acetate. The extract was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give (2′-fluorobiphenyl-2-yl) difluoroacetic acid (792 mg) as white crystals.
¹ H-NMR (CDCl ₃ ) δ: 7.00-7.10 (m, 2H), 7.16-7.23 (m, 1H), 7.28-7.32 (m, 2H), 7 .52-7.57 (m, 2H), 7.79-7.80 (m, 1H).

Reference examples 41 and 42:
Reaction and treatment were performed in the same manner as in Reference Example 40 using the corresponding starting compounds, and the compounds shown in Table 3 were obtained.

Reference Examples 43-71:
The corresponding starting materials were used and reacted and treated in the same manner as described in Reference Example 1 to obtain the compounds shown in Table 4.

Reference examples 72-73:
The corresponding starting materials were used and reacted and treated in the same manner as described in Reference Example 27 to obtain the compounds shown in Table 5.

Reference examples 74-86:
The corresponding starting materials were used and reacted and treated in the same manner as described in Reference Example 28 to obtain the compounds shown in Tables 6 and 7.

Reference Examples 94-97:
The corresponding starting materials were used and reacted and treated in the same manner as described in Reference Example 30 to obtain the compounds shown in Table 8.

Example 1:
2- (2'-fluorobiphenyl-2-yl) acetamide

(2′-Fluorobiphenyl-2-yl) acetic acid (0.96 g) obtained in Reference Example 1 was suspended in dichloromethane (8.0 ml), and DMF (0.05 ml) and oxalyl chloride (0.43 ml) were suspended. After the addition, the mixture was stirred at room temperature for 1 hour and concentrated. The obtained pale yellow crystals were dissolved in THF (3.0 ml), 28% aqueous ammonia solution (2.0 ml) was added, and the mixture was stirred at room temperature overnight. The resulting solid was filtered and dried to give 2- (2′-fluorobiphenyl-2-yl) acetamide (0.93 g) as crystals.
¹ H-NMR (CDCl ₃ ) δ: 3.50 (s, 2H), 5.24 (br, 2H), 7.13-7.44 (m, 8H)
MS (m / z) 230 (MH ^<+> ), Rt = 2.88 min.

Example 2-48:
Reaction and treatment were performed in the same manner as in Example 1 using the corresponding starting compounds, and the compounds shown in Table 9 were obtained.

Example 49:
2- (4'-Bromobiphenyl-2-yl) acetamide

2- (4′-bromobiphenyl-2-yl) acetic acid (391 mg), ammonium bicarbonate (148 mg), di-t-butyl dicarbonate (351 mg) obtained in Reference Example 15 were added to pyridine (0.5 ml) and Dissolved in a mixture of dioxane (10 ml) and stirred at room temperature overnight. Water was added to the reaction mixture, and the resulting crystals were collected by filtration to give 2- (4′-bromobiphenyl-2-yl) acetamide (356 mg) as crystals.
¹ H-NMR (CDCl ₃ ) δ: 3.52 (s, 2H), 5.33 (br, 2H), 7.17-7.21 (m, 2H), 7.26-7.39 (m , 4H), 7.53-7.56 (m, 2H).
MS (m / z) 290 (MH ^<+> ), Rt = 3.26 min.

Examples 50-52:
Reaction and treatment were performed in the same manner as in Example 49 using the corresponding starting compounds, and the compounds shown in Table 10 were obtained.

Example 53:
2- (4'-Bromobiphenyl-2-yl) -N-methylacetamide

2- (4′-bromobiphenyl-2-yl) acetic acid (391 mg), 1-ethyl-3- (3-dimethylaminopropylcarbodiimide) hydrochloride (515 mg), 1-hydroxybenzotriazole obtained in Reference Example 15 A solution of monohydrate (363 mg), methylamine hydrochloride (272 mg) and N, N-diisopropylethylamine (0.70 ml) in DMF (10 ml) was stirred at room temperature overnight. A 10% aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate, and washed successively with a saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the reaction mixture was concentrated under reduced pressure, hexane was added to the residue, the precipitated crystals were collected by filtration, and 2- (4′-bromobiphenyl-2-yl) -N-methylacetamide (353 mg). ) Was obtained as crystals.
¹ H-NMR (CDCl ₃ ) δ: 2.73 (d, 3H), 3.50 (s, 2H), 5.25 (br, 1H), 7.13-7.16 (m, 2H), 7.25-7.36 (m, 4H), 7.52-7.55 (m, 2H).
MS (m / z) 304 (MH ^<+> ), Rt = 3.32 min.

Examples 54-55:
The corresponding starting materials were used and reacted in the same manner as in Example 53 to obtain the compounds shown in Table 11.

Example 56:
2- (Biphenyl-2-yl) propanamide

2- (biphenyl-2-yl) propanoic acid (1.03 g) obtained in Reference Example 27 was suspended in dichloromethane (8.0 ml), and DMF (0.05 ml) and oxalyl chloride (0.51 ml) were added. After that, the mixture was stirred at room temperature for 1 hour and concentrated. The obtained pale yellow crystals were dissolved in THF (2.0 ml), 28% aqueous ammonia solution (1.5 ml) was added, and the mixture was stirred at room temperature overnight. The produced white solid was filtered and dried to obtain 2- (biphenyl-2-yl) propanamide (0.31 g) as crystals.
¹ H-NMR (CDCl ₃ ) δ: 1.47 (d, 3H), 3.74 (q, 1H), 5.17 (br, 2H), 7.25-7.53 (m, 9H)
MS (m / z) 226 (MH ^<+> ), Rt = 3.09 min.

Examples 57-58:
Reaction and treatment were carried out in the same manner as in Example 56 using the corresponding starting materials, and the compounds shown in Table 12 were obtained.

Example 59:
2- (Biphenyl-2-yl) -2-hydroxyacetamide

Methyl biphenyl-2-yl (hydroxy) acetate (190 mg) obtained in Reference Example 28 was dissolved in a 7 mol / l methanol solution (10 ml) of ammonia and stirred at room temperature for 60 hours. Water (20 ml) was added to the reaction solution, and methanol was distilled off under reduced pressure. The precipitated crystals were collected by filtration, washed with water and dried to give 2- (biphenyl-2-yl) -2-hydroxyacetamide (86 mg) as crystals.
¹ H-NMR (DMSO-d ₆ ) δ: 4.92 (d, 1H), 6.02 (d, 1H), 7.24-7.26 (m, 1H), 7.33-7.50 (M, 8H), 7.57-7.60 (m, 2H).
MS (m / z) 228 (MH ^<+> ), Rt = 2.52 min.

Example 60:
The starting compound obtained in 2- (2′-fluorobiphenyl-2-yl) -2-hydroxyacetamide Reference Example 29 was reacted and treated in the same manner as in Example 59 to obtain the compounds shown below.

¹ H-NMR (DMSO-d ₆ ) δ: 4.74 (br, 1H), 6.04 (d, 1H), 7.22-7.53 (m, 10H).
MS (m / z) 246 (MH ^<+> ), Rt = 2.56 min.

Example 61:
2- (biphenyl-2-yl) -2-methoxyacetamide

Biphenyl-2-yl (methoxy) acetic acid (506 mg) obtained in Reference Example 30 was dissolved in dichloromethane (10 ml), and DMF (0.05 ml) and 2M oxalyl chloride in dichloromethane (2.1 ml) were added. Stir at room temperature for 1 hour and concentrate. The obtained brown crystals were dissolved in THF (10 ml), 28% aqueous ammonia solution (2 ml) was added, and the mixture was stirred at room temperature for 2 days. To the reaction solution was added 10% aqueous citric acid solution, and the mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 2- (biphenyl-2-yl) -2-methoxyacetamide (475 mg) as crystals.
¹ H-NMR (CDCl ₃ ) δ: 3.06 (s, 3H), 4.83 (s, 1H), 5.81 (br, 1H), 6.76 (br, 1H), 7.26- 7.51 (m, 9H).
MS (m / z) 242 (MH ^<+> ), Rt = 3.05 min.

Examples 62-63:
Reaction and treatment were carried out in the same manner as in Example 61 using the corresponding starting compounds, and the compounds shown in Table 13 were obtained.

Example 64:
2- (2 ', 3', 5'-trichlorobiphenyl-2-yl) acetamide

2-bromoacetamide (3.84 g), 2,3,5-trichlorophenylboronic acid (6.04 g), tetrakis (triphenylphosphine) palladium (4.12 g), 2N aqueous sodium carbonate solution (27 ml), barium hydroxide -Octahydrate (1.12 g) and ethanol (24 ml) were added to toluene (84 ml), and the mixture was purged with nitrogen, followed by heating under reflux for 20 hours. Water was added, the mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was purified by silica gel column chromatography to obtain 2- (2 ′, 3 ′, 5′-trichlorobiphenyl-2-yl) acetamide (640 mg) as white crystals.
¹ H-NMR (CDCl ₃ ) δ: 3.36 (d, 1H), 3.47 (d, 1H), 5.25 (br, 1H), 5.33 (br, 1H), 7.17-7.19 (m, 2H), 7.36-7.46 (m, 3H), 7.53 (d, 1H).
MS (m / z) 314 (MH ^<+> ), Rt = 4.41 min ^* .

Examples 65-108:
Reaction and treatment were performed in the same manner as in Example 64 using the corresponding starting compounds, and the compounds shown in Table 14 were obtained.

Examples 109-173:
The corresponding starting materials were used and reacted in the same manner as in Example 1 to obtain the compounds shown in Table 15.

Example 174:
Reaction and treatment were carried out in the same manner as in Example 49 using the corresponding starting compounds, and the compounds shown in Table 16 were obtained.

Examples 175-177:
Reaction and treatment were carried out in the same manner as in Example 56 using the corresponding starting materials, and the compounds shown in Table 17 were obtained.

Examples 178-198:
The corresponding starting materials were used and reacted in the same manner as in Example 59 to obtain the compounds shown in Table 18 and Table 19.

Examples 199-206:
Reaction and treatment were carried out in the same manner as in Example 61 using the corresponding starting compounds, and the compounds shown in Table 20 were obtained.

Examples 207 and 208:
2- (biphenyl-2-yl) -2R-hydroxyacetamide and 2- (biphenyl-2-yl) -2S-hydroxyacetamide

The compound of Example 59 was fractionated with CHIRALPAK IA (mobile phase: Hex-EtOH-MeOH) manufactured by Daicel to obtain a front peak (enantiomer A) and a rear peak (enantiomer B).
Example 207 (enantiomer A): retention time 4.13 minutes Chiral HPLC (Chiralpak IA, 0.46 cm I.D. x 25 cmL, mobile phase: Hex / EtOH / MeOH = 60/20/20, flow rate: 1.0 ml / min, temperature : 40 ° C., wavelength: 260 nm), [α] D 20.4 = + 127.0 ° (c 0.521, CH 3 OH)
Example 208 (enantiomer B): retention time 6.99 minutes Chiral HPLC (Chiralpak IA, 0.46 cm I.D. x 25 cmL, mobile phase: Hex / EtOH / MeOH = 60/20/20, flow rate: 1.0 ml / min, temperature : 40 ° C., wavelength: 260 nm), [α] D 20.4 = −125.8 ° (c 0.985, CH 3 OH)

Examples 209-214:
The corresponding starting materials were used and reacted and treated in the same manner as in Examples 207 and 208 to obtain the compounds shown in Table 21.

Examples 215 and 216:
2- (3 ', 5'-dichlorobiphenyl-2-yl) -2R-hydroxyacetamide and 2- (3', 5'-dichlorobiphenyl-2-yl) -2S-hydroxyacetamide

[Step 1]: Example 183 (2.62 g) was dissolved in 34 ml of toluene, pyridinium p-toluenesulfonic acid (22 mg), (S) -allyl-2-oxabicyclo [3,3,0] oct-8. -Ene (2.66 g) was added and stirred at room temperature for 1 hour. Saturated aqueous sodium hydrogen carbonate solution was added to terminate the reaction, and the mixture was extracted with ethyl acetate. After washing with saturated brine and washing with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. The diastereomers were separated by silica gel column chromatography to obtain a first eluate (1.74 g) and a second eluate (1.66 g) as white crystals.
First eluate: ¹ H-NMR (CDCl ₃ ) δ: 1.48-1.68 (m, 6H), 1.75-1.81 (m, 1H), 1.90-1.94 (m , 1H), 2.12-2.17 (m, 1H), 2.29-2.34 (m, 1H), 3.04 (dd, 1H), 3.50-3.56 (m, 1H) ), 5.07-5.14 (m, 2H), 5.20 (s, 1H), 5.43 (br, 1H), 5.78-5.88 (m, 1H), 6.63 ( br, 1H), 7.18 (dd, 1H), 7.29-7.40 (m, 3H), 7.48 (d, 1H), 7.53 (d, 2H).
Second eluate: ¹ H-NMR (CDCl ₃ ) δ: 0.94-1.03 (m, 1H), 1.37-1.52 (m, 5H), 1.70-1.77 (m , 1H), 1.93-1.98 (m, 1H), 2.09-2.14 (m, 1H), 2.21-2.26 (m, 1H), 3.71-3.77. (M, 1H), 3.82-3.87 (m, 1H), 5.06-5.14 (m, 2H), 5.30 (s, 1H), 5.47 (br, 1H), 5.75-5.85 (m, 1H), 6.74 (br, 1H), 7.20-7.22 (m, 1H), 7.32-7.42 (m, 3H), 7. 48-7.51 (m, 1H), 7.54 (br, 2H).

[Step 2]: Ether (1.74 g) as the first eluate was dissolved in methanol (20 ml), p-toluenesulfonic acid monohydrate (74 mg) was added, and the mixture was stirred at room temperature for 8 hours. A saturated aqueous sodium hydrogen carbonate solution was added to terminate the reaction, and the mixture was extracted with chloroform. After drying over anhydrous magnesium sulfate and evaporating the solvent under reduced pressure, the residue was purified by silica gel column chromatography to obtain alcohol (896 mg) as a white amorphous.
Example 215 (enantiomer A): retention time 13.3 minutes Chiral HPLC (Daicel Chiralpak AD-H, 0.46 cm I.D. x 25 cmL, mobile phase: Hex / EtOH = 90/10, flow rate: 1.0 ml / min, Temperature: 30 ° C., wavelength: 254 nm).

Ether (1.74 g) as the second eluate was dissolved in methanol (20 ml), p-toluenesulfonic acid monohydrate (71 mg) was added, and the mixture was stirred at room temperature for 8 hours. A saturated aqueous sodium hydrogen carbonate solution was added to terminate the reaction, and the mixture was extracted with chloroform. After drying over anhydrous magnesium sulfate and evaporating the solvent under reduced pressure, the residue was purified by silica gel column chromatography to obtain alcohol (783 mg) as a white amorphous.
Example 216 (enantiomer B): retention time 14.2 minutes Chiral HPLC (Daicel Chiralpak AD-H, 0.46 cm I.D. x 25 cmL, mobile phase: Hex / EtOH = 90/10, flow rate: 1.0 ml / min, Temperature: 30 ° C., wavelength: 254 nm).

Examples 217-220:
Reaction and treatment were carried out in the same manner as in Examples 215 and 216 using the corresponding starting compounds, and the compounds shown in Table 22 were obtained.

Test Examples Hereinafter, pharmacological test results of representative compounds of the present invention will be shown and the pharmacological action of the compounds will be described. However, the present invention is not limited to these test examples.

For evaluation of antiepileptic drugs, the maximum electric shock convulsion model (MES) evaluation, the subcutaneous pentetrazole model (minimum convulsion model, scPTZ) evaluation, and the rat amygdala kindling model evaluation, which are typically highly clinically predictable, are used. A compound showing anticonvulsant activity in any of these models is expected as a drug showing a sure antiepileptic activity in clinical practice. Furthermore, a compound showing an equivalent anticonvulsant activity in both MES evaluation and scPTZ evaluation is expected to have a broad spectrum of antiepileptic spectrum that is widely effective against partial seizures and general seizures like valproic acid. In addition, a 6 Hz psychomotor seizure model that is resistant to existing antiepileptic drugs has been used for the evaluation of new antiepileptic drugs. In this model, compounds that exhibit anticonvulsant activity are existing antiepileptic drugs. It is expected to be effective for patients who are resistant to treatment. As described above, a compound that equally exhibits anti-MES activity, anti-scPTZ activity, and anti-6 Hz model activity can be a therapeutic agent that has rare clinical utility in existing agents.
In addition, no valid animal model with high clinical predictability has been reported yet to evaluate the improvement effect on bipolar disorder, but the pathological conditions of the “disease state” and “depressed state” that are the background of this disease are captured. Some animal models have been reported, and as representative models of each, excessive hyperactivity state (depression state) observed when methamphetamine and chlordiazepoxide were administered in combination, and immobility state (depression state) seen during forced swimming The improvement evaluation using the index is generally used. Compounds that show improvement activity against both of these models can be expected as an effect of stabilizing the mood change of this disease state.

Test Example 1: Maximum Electric Shock Convulsion Model (MES) Evaluation This test is a test for evaluating the anticonvulsant action of a drug. The animal model used in this study is an expression system for generalized tonic clonic seizures and secondary generalized partial seizures. Test compounds 50 and 100 mg / kg were orally administered to Slc: ddY male mice (3 mice per group, body weight 20-30 g), and after 1 hour, electrical stimulation (60 Hz, 25 mA, 0.2 seconds) was given from the cornea. Suppression of the development of tonic extension spasms in the hind limbs was observed. As a control, 0.5% tragacanth solution or 0.5% methylcellulose solution was administered. The results are shown in Table 19 below.

Test Example 2: Subcutaneous Injection Pentetrazole Model (Minimum Spasm Model, scPTZ) Evaluation This test is a test for evaluating the anticonvulsant action of a drug in the same manner as Test Example 1. Unlike the expression system of Test Example 1, the animal model used in this test is an expression system for generalized absence seizures and myoclonic attacks. Test compounds 50 and 100 mg / kg were orally administered to Slc: ddY male mice (3 mice per group, body weight 20-30 g), and pentetrazole 85 mg / kg was subcutaneously administered 1 hour later. Thereafter, the presence or absence of clonic convulsions during 30 minutes was observed. As a control, 0.5% tragacanth solution or 0.5% methylcellulose solution was administered. The results are shown in Table 23 below.

  As shown in Table 23, the compounds according to the present invention exhibited anticonvulsant activity in the maximum electric shock convulsion model (MES) evaluation and / or the subcutaneous injection pentetrazole model (minimum convulsion model, scPTZ) evaluation by oral administration. Examples 1, 13, 16, 20, 25, 41, 57, 67, 71, 80, 88, 90, 91, 109, 140, 152, 162, 178, 183, 185, 186, 190, 207, 209, Compounds 210, 211 and 212 showed strong anticonvulsant activity in both evaluations.

Test Example 3: Rat Amygdala Kindling Model Evaluation This test is a test for evaluating the anticonvulsant action of drugs in rats in addition to mice. The animal model (kindling model) used in this study is similar to the clinical findings of focal simple partial attacks, complex partial attacks, and secondary generalized partial attacks, and is known to have extremely high clinical predictability. ing. Slc: A chronic electrode was placed in the cerebral cortex (front and back) and amygdala of Wistar male rats (body weight 250 to 300 g), and electrical stimulation was performed once a day for about 2 weeks to the amygdala from the first week after surgery. (50 Hz, 400 μA, 1 second). Stimulation conditions were determined according to the method of Loscher et al. [Epilepsy Res. 40: 63-77 (2000)]. Also, the method of Racine et al. [Motor size. Electroenceph. Clin. Neurophysiol. , 32: 281-294 (1972)], the stimulation was continued until 10 episodes of stage 5 were continuously expressed, and a kindling model was completed. Test compounds are orally administered to the completed model at 100 mg / kg each, 1 hour after administration, the threshold stimulation current at which seizures are induced (seizure threshold), the duration of post-emergence observed on the electroencephalogram (post-emission time) In addition, seizure severity (stage score 1-5) was evaluated as an index. The seizure threshold and post-release time were expressed as the average rate of change for each value before test compound administration. As a control, 0.5% tragacanth solution was administered. The results are shown in Table 24. Minus means decrease or shorten.

  As shown in Table 24, the compounds of Examples 1 and 25 showed high efficacy against each index in the rat amygdala kindling model by oral administration of 100 mg / kg.

Test Example 4: Evaluation of 6 Hz psychomotor seizure model This test is a test for evaluating the anticonvulsant action of a drug in the same manner as Test Example 1 and Test Example 2. Unlike Test Example 1 and Test Example 2, the animal model used in this test is a seizure phenotype showing resistance to treatment with existing antiepileptic drugs. Slc: ddy male mice (group 5 mice, body weight 20-30g) were orally administered test compound 100 mg / kg, and after 30 minutes or 1 hour, electrical stimulation (6Hz, 32mA, 3 seconds) was given from the cornea and induced We observed the presence or absence of the occurrence of clonic convulsions, tail reaction, and immobility in the forelimbs. As a control, 0.5% tragacanth solution, 0.5% methylcellulose solution, or olive oil was administered. The results are shown in Table 25.

  As shown in Table 25, the compounds of Examples 1, 25, 91, 185, 190 and 207 showed high efficacy against a 6 Hz psychomotor seizure model at 100 mg / kg orally.

Test Example 5: Rotor rod evaluation This test is a test for evaluating the coordinated motor ability inhibitory action of drugs. Slc: ddy male mice (body weight 20-30 g) are trained to be able to walk without dropping for 3 minutes with a rotor rod device (a device that rotates a cylindrical rod with a diameter of 4 cm, 13 rpm) on the day before the test. The test compound was orally administered to 10 mice per group, and after 1 hour, the test compound was placed on the rotarod apparatus in the same manner as described above, and the walking state was observed for 100 seconds. Animals that fell due to coordination impairment within 100 seconds were counted as positive. As a control, 0.5% methylcellulose solution was administered. The results are shown in Table 26.

Test Example 6: Evaluation of antidepressant This test is a representative test for evaluating the antidepressant action of drugs (Porsolt et al., Nature, 266: 730-732, 1977, Porsolt et al., Eur. J. Pharmacol., 47 : 379-391, 1978). Crl: Forced swimming of CD (SD) male rats (12 per group, weight 200-250g) for 15 minutes in a 200 mm diameter aquarium with water accumulated to a depth (205 mm) where the hind limbs cannot contact the bottom surface The test compound was orally administered 15 minutes after the end of swimming. The next day, the same dose of the test compound was administered, and the test compound was transferred to the water tank for 5 minutes at the same time as the previous day, and the immobility time during which no swimming action was performed was measured. The antidepressant action was evaluated by the degree of shortening of the immobility time for the control group. The control group received 0.5% methylcellulose solution. In addition, Lamotrigine, which is indicated for bipolar disorder under the above conditions, shortened the immobility time in a dose-dependent manner. The results are shown in Table 27.

Test Example 7: Antiepileptic Evaluation This test is a test for evaluating the antiepileptic effect of a drug. This evaluation system is a test system that can confirm the effectiveness of an antidepressant drug used clinically as a mood stabilizer different from the schizophrenia drug (Arban et al., Behav. Brain Res., 158: 123 -132, 2005, Foreman et al., Pharmacol. Biochem. Behav., 89: 523-534, 2008). The test compound was orally administered to Slc: C57BL / 6J male mice (8 mice per group, body weight 20 to 26 g), and methamphetamine (4 mg / kg) and chlordiazepoxide (10 mg / kg) were intraperitoneally administered 30 minutes later. Thereafter, the animal was allowed to move freely in an acrylic cage (inner dimensions: W360 mm × D230 mm × H310 mm) for 90 minutes, and the moving distance of the animal was measured using Ethovision software (Ver.3.1). The movement distance of the latter half 60 minutes excluding the new environment acclimation time of 30 minutes was used as a measurement value. Anti-depressive effect was evaluated by the degree of shortening relative to the control group. In the control group, 0.5% methylcellulose solution was administered. Under the above conditions, Lamotrigine, which has clinical indications for bipolar disorder, shortened the travel distance in a dose-dependent manner. The results are shown in Table 28.

Formulation Example 1: Manufacture of tablets
The compound of Example 1 (250 g), corn starch (54 g), carboxymethylcellulose calcium (40 g), crystalline cellulose (50 g) and magnesium stearate (6 g) were mixed and granulated by a conventional method, and beaten at 400 mg per tablet. Lock and make 1000 tablets.

Formulation Example 2: Preparation of powder After mixing the compound of Example 1 (500 g), lactose (470 g), hydroxypropyl cellulose (25 g) and light anhydrous silicic acid (5 g), a powder is prepared.

  As described above, the biphenylacetamide derivative of the present invention is evaluated by the maximum electric shock convulsion model (MES), which is a representative evaluation model of antiepileptic drugs, the evaluation of a subcutaneous injection pentetrazole model (minimum convulsion model, scPTZ), and a 6 Hz spirit. Strong anticonvulsant activity in all motor seizure model evaluation and / or rat amygdala kindling model evaluation. Thus, the compounds according to the invention are antiepileptic drugs (eg partial seizures including simple partial seizures, complex partial seizures and persistent generalized seizures with loss of consciousness, absence seizures, myoclonic seizures, clonic seizures). , Prophylactic and / or therapeutic agents for generalized seizures such as tonic seizures, tonic-clonic seizures, weakness seizures, West syndrome and Lennox-Gastaut syndrome). In addition, these group of compounds of the present invention are also expected as preventive and / or therapeutic agents for intractable epileptic seizures for which pharmacotherapy is not yet effective. Furthermore, since it shows effectiveness in antidepressant evaluation and antidepressant evaluation, the compound according to the present invention is also useful as an antidepressant, an antidepressant and / or a therapeutic and / or preventive for bipolar disorder.

Claims (15)

The following formula (A):
[Where:
R ¹ , R ² , R ³ , R ^a and R ^b are bonded one by one to any substitutable carbon atom on the benzene ring to which they are bonded, and are the same or different and each represents a hydrogen atom, a fluorine atom, chlorine Represents an atom, bromine atom, C _1-6 alkyl, C _1-6 alkoxy substituted with 1 to 3 fluorine atoms, C _1-6 alkyl-S (O) _n — or cyano, S (O) _n -may be substituted with 1 to 5 fluorine atoms, wherein any ^{two of} R ¹ , R ² , R ³ , R ^a and R ^b are 2 When '-methyl and 3'-methyl, any one of the remaining groups is a group other than a hydrogen atom;
R ⁴ , R ⁵ , R ^c and R ^d are bonded one by one to any substitutable carbon atom on the benzene ring to which they are bonded, and are the same or different and each represents a hydrogen atom, a fluorine atom, a chlorine atom, C _1-6 alkyl, C _1-6 alkoxy substituted with 1 to 3 fluorine atoms, C _1-6 alkyl-S (O) _n —, cyano or nitro, wherein the alkyl or alkyl-S (O) _n − may be substituted with 1 to 5 fluorine atoms,
R ⁶ and R ⁷ are the same or different and each represents a hydrogen atom, a fluorine atom, methyl, ethyl, a hydroxyl group or C _1-6 alkoxy (however, when one is a hydroxyl group, the other is a fluorine atom, a hydroxyl group or C _{1) -6} not alkoxy), or together with the carbon atoms to constitute the C _3-6 cycloalkyl which binds to, the methyl, ethyl, alkoxy and cycloalkyl are optionally substituted with 1-5 fluorine atoms You may,
R ⁸ and R ⁹ are the same or different and each represents a hydrogen atom, C _1-6 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl or C _3-6 cycloalkyl, and the alkyl, cycloalkyl-alkyl And cycloalkyl may be substituted with 1 to 5 fluorine atoms,
n represents an integer of 0 to 2,
However, when R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ^a , R ^b , R ^c and R ^d are all hydrogen atoms and R ⁶ and R ⁷ are both hydrogen atoms, R ^{One of 8} and R ⁹ is a hydrogen atom,
When R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ^a , R ^b , R ^c and R ^d are all hydrogen atoms and any one of R ⁶ and R ⁷ is alkoxy, R ⁸ and R ⁹ are the same or different and each represents a hydrogen atom, C _1-3 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl or C _3-6 cycloalkyl. ]
Or a hydrate or solvate thereof. The medicament according to claim 1, wherein R ^a , R ^b , R ^c and R ^d are all hydrogen atoms. R ⁸ and R ⁹ are the same or different and each represents a hydrogen atom, C _1-3 alkyl, C _3-7 cycloalkyl-C _1-3 alkyl or C _3-6 cycloalkyl, and the alkyl, cycloalkyl-alkyl And cycloalkyl may be substituted with 1 to 5 fluorine atoms. Here, when R ¹ , R ² , R ³ , R ⁴ and R ⁵ are all hydrogen atoms, R ⁸ and R ⁹ are substituted. Any one of which is a hydrogen atom,
The medicament according to claim 2. R ¹ , R ² and R ³ are the same or different and each represents a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, trifluoromethyl, trifluoromethoxy, C _1-3 alkyl-S (O) _n — or cyano. And the alkyl-S (O) _n — may be substituted with 1 to 5 fluorine atoms,
The medicine according to claim 2 or claim 3. R ¹ , R ² and R ³ are the same or different and are a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, trifluoromethyl or trifluoromethoxy.
The compound according to claim 2 or claim 3, or a hydrate or solvate thereof. The pharmaceutical according to any one of claims 2 to 5, wherein R ⁹ is a hydrogen atom. R ⁴ and R ⁵ are the same or different and are a hydrogen atom, a fluorine atom, a chlorine atom, C _1-3 alkyl, trifluoromethyl or trifluoromethoxy.
The medicine according to any one of claims 2 to 6. R ⁶ and R ⁷ are the same or different and are a hydrogen atom, methyl, ethyl, hydroxyl group or C _1-3 alkoxy (provided that one is a hydroxyl group, the other is not a hydroxyl group or C _1-3 alkoxy),
The medicine according to any one of claims 2 to 7. R ¹ , R ² and R ³ are the same or different and are a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, trifluoromethyl or trifluoromethoxy;
R ⁴ and R ⁵ are the same or different and are a hydrogen atom, a fluorine atom, a chlorine atom, trifluoromethyl or trifluoromethoxy;
R ⁶ and R ⁷ are the same or different and are a hydrogen atom, methyl, hydroxyl group or methoxy (provided that one is a hydroxyl group, the other is not a hydroxyl group or methoxy),
R ⁸ is a hydrogen atom, methyl or ethyl,
R ⁹ is a hydrogen atom,
The medicament according to claim 2. The medicament according to claim 2 or 9, wherein R ¹ , R ² , R ³ , R ⁴ and R ⁵ are not all hydrogen atoms. The medicament according to claim 2, comprising a biphenylacetamide derivative selected from the following compounds, or a hydrate or solvate thereof:
N, N-dimethyl-2- [4 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- [3 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
N-methyl-2- [3 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
N-methyl-2- [2 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
N-ethyl-2- [2 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- (3 ′, 4′-difluorobiphenyl-2-yl) acetamide,
2- (4′-fluorobiphenyl-2-yl) acetamide,
2- (4′-fluorobiphenyl-2-yl) -N-methylacetamide,
2- (3′-fluorobiphenyl-2-yl) -N-methylacetamide,
2- (2′-fluorobiphenyl-2-yl) -N-methylacetamide,
2- (2′-fluorobiphenyl-2-yl) -N, N-dimethylacetamide,
N-methyl-2- (3′-methylbiphenyl-2-yl) -acetamide,
2- (5-fluorobiphenyl-2-yl) acetamide,
2- (4-fluorobiphenyl-2-yl) -N-methylacetamide,
2- (2 ′, 4-difluorobiphenyl-2-yl) acetamide,
2- (2 ′, 4-difluorobiphenyl-2-yl) -N-methylacetamide,
2- (3′-chloro-4-fluorobiphenyl-2-yl) acetamide,
2- (4′-bromobiphenyl-2-yl) acetamide,
2- (biphenyl-2-yl) acetamide,
2- (3′-bromobiphenyl-2-yl) acetamide,
2- (4′-bromobiphenyl-2-yl) -N-methylacetamide,
2- (biphenyl-2-yl) -N-methylacetamide,
2- (biphenyl-2-yl) propanamide,
2- (2′-fluorobiphenyl-2-yl) -N-methylpropanamide,
2- (biphenyl-2-yl) -2-hydroxyacetamide,
2- (2′-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (biphenyl-2-yl) -2-methoxyacetamide,
2- (biphenyl-2-yl) -2-methoxy-N-methylacetamide,
2- (biphenyl-2-yl) -2-methoxy-N, N-dimethylacetamide,
2- (2 ′, 3 ′, 5′-trichlorobiphenyl-2-yl) acetamide,
2- (4′-chloro-2′-fluorobiphenyl-2-yl) acetamide,
2- [3′-fluoro-4 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide,
2- [3′-fluoro-5 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- [4′-chloro-3 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- [4 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide,
2- (2 ′, 4′-dichlorobiphenyl-2-yl) acetamide,
2- [3 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide,
2- [2′-fluoro-5 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- [2′-chloro-4 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- (2′-chloro-3′-fluorobiphenyl-2-yl) acetamide,
2- (5′-chloro-2′-fluorobiphenyl-2-yl) acetamide,
2- (2 ′, 3 ′, 4′-trifluorobiphenyl-2-yl) acetamide,
2- [2′-fluoro-5 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide,
2- (2 ′, 5′-dichlorobiphenyl-2-yl) acetamide,
N-methyl-2- [3 ′-(trifluoromethoxy) biphenyl-2-yl] acetamide,
2- (2′-fluoro-5-nitrobiphenyl-2-yl) acetamide,
2- (3-fluorobiphenyl-2-yl) acetamide,
2- (3-fluorobiphenyl-2-yl) -N-methylacetamide,
2- (5-chlorobiphenyl-2-yl) -N-methylacetamide,
2- (5-chloro-2′-fluorobiphenyl-2-yl) acetamide,
2- (5-chloro-2′-fluorobiphenyl-2-yl) -N-methylacetamide,
2- [4-chloro-4 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- [3′-fluoro-5- (trifluoromethyl) biphenyl-2-yl] acetamide,
2- (3 ′, 5′-dichloro-5-fluorobiphenyl-2-yl) acetamide,
2- (3 ′, 5′-difluorobiphenyl-2-yl) acetamide,
1- (2′-fluorobiphenyl-2-yl) -N-methylcyclopropanecarboxamide,
1- (3′-fluorobiphenyl-2-yl) -N-methylcyclopropanecarboxamide,
2-fluoro-2- (3′-fluorobiphenyl-2-yl) acetamide,
2-fluoro-2- (2′-fluorobiphenyl-2-yl) -N-methylacetamide,
2-fluoro-2- (4′-fluorobiphenyl-2-yl) -N-methylacetamide,
2- (3′-chlorobiphenyl-2-yl) -2-fluoroacetamide,
2,2-difluoro-2- (3′-fluorobiphenyl-2-yl) acetamide,
2- (3′-chlorobiphenyl-2-yl) -2,2-difluoroacetamide,
2- (biphenyl-2-yl) -2,2-difluoroacetamide,
2- (3′-fluorobiphenyl-2-yl) propanamide,
2- (5-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (3 ′, 5-difluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (3 ′, 5′-dichloro-5-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (3 ′, 4-difluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (3 ′, 5′-dichloro-4-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (5′-chloro-2′-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (2′-fluorobiphenyl-2-yl) -2-methoxyacetamide,
2- (2′-fluorobiphenyl-2-yl) -2-methoxy-N-methylacetamide,
2- (2′-fluorobiphenyl-2-yl) -2-methoxy-N, N-dimethylacetamide,
2- (4′-fluorobiphenyl-2-yl) -2-methoxyacetamide,
2- (4′-fluorobiphenyl-2-yl) -2-methoxy-N, N-dimethylacetamide and 2- (3′-chlorobiphenyl-2-yl) -2-methoxyacetamide. The medicament according to claim 2, comprising a biphenylacetamide derivative selected from the following compounds, or a hydrate or solvate thereof:
2- (2′-fluorobiphenyl-2-yl) acetamide,
N-methyl-2- [4 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- (3′-chlorobiphenyl-2-yl) acetamide,
2- (2′-chlorobiphenyl-2-yl) acetamide,
2- (2 ′, 3′-difluorobiphenyl-2-yl) acetamide,
2- (3′-fluorobiphenyl-2-yl) acetamide,
2- (2 ′, 5-difluorobiphenyl-2-yl) acetamide,
2- (4-fluorobiphenyl-2-yl) acetamide,
2- (biphenyl-2-yl) -N-methylpropanamide,
2- (biphenyl-2-yl) -2-hydroxyacetamide,
2- (2′-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (2 ′, 3 ′, 5′-trifluorobiphenyl-2-yl) acetamide,
2- (3 ′, 5′-dichlorobiphenyl-2-yl) acetamide,
2- (3′-chloro-5′-fluorobiphenyl-2-yl) acetamide,
2- (2′-chloro-5′-fluorobiphenyl-2-yl) acetamide,
2- (3 ′, 4 ′, 5′-trifluorobiphenyl-2-yl) acetamide,
2- [5′-chloro-2 ′-(trifluoromethyl) biphenyl-2-yl] acetamide,
2- (4,4′-dichlorobiphenyl-2-yl) acetamide,
2- (4,4′-difluorobiphenyl-2-yl) acetamide,
2- (4,4′-difluorobiphenyl-2-yl) -N-methylacetamide,
2- (3,3′-difluorobiphenyl-2-yl) acetamide,
2- (2 ′, 5′-difluorobiphenyl-2-yl) acetamide,
2- (biphenyl-2-yl) -2-fluoroacetamide,
2-fluoro-2- (2′-fluorobiphenyl-2-yl) acetamide,
2- (3′-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (3 ′, 5′-dichlorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (2′-chloro-5′-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (4-fluorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (2′-chlorobiphenyl-2-yl) -2-hydroxyacetamide,
2- (3'-Chloro-5'-fluorobiphenyl-2-yl) -2-hydroxyacetamide and 2-hydroxy-2- (3 ', 4', 5'-trifluorobiphenyl-2-yl) acetamide .   A pharmaceutical composition comprising the medicament according to any one of claims 1 to 12, and a pharmaceutically acceptable carrier.   The medicament according to any one of claims 1 to 12, which is an antiepileptic drug or a mood stabilizer for bipolar disorder.   The medicament according to any one of claims 1 to 12, which is a therapeutic or prophylactic agent for epilepsy and / or bipolar disorder.